IUSCC- 0551  
Version 04/07/2021 NCT #02619253 1 
   
     
A Phase I /Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics 
and Effica cy of Pembrolizumab (MK -3475)  in Combination with Vorinostat in Patients 
with Advanced Prostate, Renal or Urothelial Cell Carcinoma  
 
Protocol Number:  
IUSCC- 0551 
 
Coordinating Center:  
Indiana University Melvin and Bren Simon Comprehensive Cancer Center  
 
Principal Investigator:  
Nabil Adra , MD 
535 Barnhill Drive, RT 400 
Indianapolis, IN 46202  
317-944-5349 
nadra@iu.edu 
 
Co-Investigator s: 
David Quinn, MBBS, PhD, FRACP, FACP ( USC/Norris CCC)  
Noah Hahn, MD  (Johns Hopkins University)  
Ted Logan, MD ( Indiana University ) 
Roberto Pili, MD  
 
Research Nurses : 
Sheila Dropcho, RN  
Marietta Moore, RN  
Christin Snow, RN , BSN  
  
Study Statistician:  
Hao Liu, PhD  
 
Support Provided By:  
Merck  
 
Protocol Version  Date : 
April 07, 20 21 
 
  
IUSCC- 0551  
Version 04/07/2021 NCT #02619253 2 
 IND# s: 
128468  
Sponsor -Investigator – Nabil Adra , MD  
Investigational Agents -  vorinostat and pembrolizumab  
 
138531 
Sponsor -Investigator - James W. Fletcher, MD  
Investigational Agent -  68Ga -PSMA -11 
IUSCC- 0551  
Version 04/07/2021 NCT #02619253 3 
 PROTOCOL SIGNATURE PAGE 
 
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and 
Efficacy of Pembrolizumab (MK -3475) in Combination with Vorinostat in Patients with 
Advanced Prostate, Renal or Urothelial Cell Carcinoma  
 
VERSION DATE:  07April 2021 
 
I confirm I have read this protocol, I understand it, and I will work according to this protocol 
and to the ethical principles stated in the latest version of the Declaration of Helsinki, the applicable guidelines for good clinical practices, or the applic able laws and regulations of the 
country of the study site for which I am responsible, whichever provides the greater protection of the individual.  I will accept the monitor’s overseeing of the study.  I will 
promptly submit the protocol to applicable eth ical review board(s).  
 
 
 
 
 
 
 
 ____________________________________ ________________________ 
 Signature of Site Investigator        Date  
 
 ____________________________________  Site Investigator Name (printed)  
  ____________________________________ 
 Site Investigator Title  
 
 
____________________________________  Name of Facility  
  
____________________________________ 
 Location of Facility (City and State)  
 
 
PLASE COMPLETE AND EMAIL COPY TO INDIANA UNIVERSITY SIMON 
COMPREHENSIVE CANCER CENTER CLINICAL TRIALS OFFICE  Instructions to the investigator: Please SIGN and DATE this signature 
page. PRINT your name and title, the name and location of the 
facility in which the study will be conducted, and the expected IRB 
approval date. Scan and email t he completed form to Indiana 
University Simon Comprehensive Cancer Center and keep a record for 
your files.  
IUSCC- 0551  
Version 04/07/2021 NCT #02619253 4 
 TABLE OF CONTENTS  
1.0 TRIAL SUMMARY  ..................................................................................................... 7 
2.0 TRIAL DESIGN ........................................................................................................... 7 
2.1 Trial Design  .............................................................................................................. 7 
2.2 Trial Diagram ............................................................................................................ 9 
3.0 OBJECTIVES  ............................................................................................................... 9 
3.1 Primary Objective  ..................................................................................................... 9 
3.2 Secondary Objectives  ............................................................................................... 9 
3.3 Correlative Objective  ................................................................................................ 9 
4.0 BACKGROUND & RATIONALE  .............................................................................. 9 
4.1 Background ............................................................................................................... 9 
4.2 Rationale  ................................................................................................................. 11 
5.0 METHODOLOGY  ..................................................................................................... 13 
5.1 Entry Criteria  .......................................................................................................... 13 
5.2 Trial Treatments  ...................................................................................................... 16 
5.3 Concomitant Medications/Vaccinations (allowed & prohibited) ........................... 27 
5.4 Rescue Medications & Supportive Care  ................................................................. 28 
5.5 Diet/Activity/Other Considerations  ........................................................................ 29 
5.6 Subject Withdrawal/Discontinuation Criteria  ......................................................... 30 
5.7 Discontinuation of Study Therapy after CR  ........................................................... 31 
5.8 Subject Replacement Strategy  ................................................................................ 31 
5.9 Pseudoprogression  .................................................................................................. 31 
5.10  Clinical Criteria for Early Trial Termination  .......................................................... 31 
6.0 SCHEDULE OF ASSESSMENTS  ............................................................................. 33 
7.0 TRIAL PROCEDURES  .............................................................................................. 36 
7.1 Trial Procedures  ...................................................................................................... 36 
7.2 Assessing and Recording of Adverse Events  ......................................................... 45 
7.3 Participating Site Reporting Responsibilities  ......................................................... 51 
7.4 Coordinating Center Reporting Responsibilities  .................................................... 52 
8.0 STATISTICAL METHODS  ....................................................................................... 55 
8.1 General Considerations  ........................................................................................... 55 
8.2 Study Design ........................................................................................................... 55 
8.3 Analysis Populations  ............................................................................................... 55 
8.4 Sample Size, Accrual and Study Duration  .............................................................. 55 
IUSCC- 0551  
Version 04/07/2021 NCT #02619253 5 
 8.5 Patient Characteristics  ............................................................................................. 56 
8.6 Significant Protocol Violations  ............................................................................... 56 
8.7 Concomitant Medications ....................................................................................... 56 
8.8 Exposure and Compliance  ...................................................................................... 56 
8.9 Efficacy Analysis  .................................................................................................... 56 
8.10  Safety Analysis  ....................................................................................................... 56 
8.11  Interim Analysis  ...................................................................................................... 57 
9.0 DATA AND SAFETY Monitoring  ............................................................................ 57 
9.1 Data Safety Monitoring Committee  ........................................................................ 57 
9.2 DSMC DLT Review ............................................................................................... 58 
9.3 IND Annual Reports  ............................................................................................... 58 
9.4 Study Auditing and Monitoring  .............................................................................. 58 
9.5 Data Management/ Oncore Reporting Requirements  ............................................. 58 
9.6 Study Accrual Oversight  ......................................................................................... 58 
9.7 Oncore Safety Reporting  ........................................................................................ 58 
9.8 Protocol Deviation Reporting  ................................................................................. 59 
9.9 Data Acquisition  ..................................................................................................... 59 
10.0  MULTICENTER GUIDELINES ................................................................................ 59 
10.1  Study Documents  .................................................................................................... 59 
10.2  Study Initiation ....................................................................................................... 59 
10.3  Patient Enrollment  .................................................................................................. 60 
10.4  Data Monitoring  ...................................................................................................... 60 
10.5  Record Retention  .................................................................................................... 60 
11.0  LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES ................................................................................................................... 60 
11.1  Investigational Product  ........................................................................................... 60 
11.2  Packaging and Labeling Information  ...................................................................... 62 
11.3  Clinical Supplies Disclosure  ................................................................................... 62 
11.4  Storage and Handling Requirements  ...................................................................... 62 
11.5  Returns and Reconciliation ..................................................................................... 62 
12.0  ADMINISTRATIVE AND REGULATORY DETAILS  ........................................... 63 
12.1  Compliance with Trial Registration and Results Posting Requirements  ................ 63 
13.0  REFERENCES ........................................................................................................... 64 
14.0  APPENDICES ............................................................................................................ 65 
14.1  ECOG Performance Status  ..................................................................................... 65 
14.2  Common Terminology Criteria for Adverse Events V4.0 (CTCAE)  ..................... 65 
IUSCC- 0551  
Version 04/07/2021 NCT #02619253 6 
 14.3  Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria for 
Evaluating Response in Solid Tumors  .................................................................... 65 
14.4  Drug Diary  .............................................................................................................. 69 
14.5  Events of Clinical Interest Guidance Document  ..................................................... 70 
14.6  Woman of Childbearing Potential (WOCBP) definition  ........................................ 70 
14.7  Immune -Related Response Criteria  ........................................................................ 71 
 
IUSCC-0551  
Version 04/07/2021 NCT #02619253 7 
 1.0 TRIAL SUMMARY  
Abbreviated Title  Vorinostat and  pembrolizumab  in prostate, urothelial and renal cell 
carcinoma  
Trial Phase  I/Ib 
Clinical Indication  Metastatic disease  
Trial Type  Interventional  
Route of administration  IV and oral  
Trial Blinding  N/A 
Treatment Groups  Anti-PD1/PD-L1 naïve and anti -PD1/PD-L1 resistant tumors  
Number of trial subjects  51-57 
Estimated enrollment period  18 months  
Estimated duration of trial  24 months  
Duration of Participation  24 months  
 
 
 
2.0 TRIAL DESIGN 
2.1 Trial Design  
This is a Phase I/Ib , open-label, safety, and pharmacodynamics study of pembrolizumab  in 
combination with vorinostat in patients with advanced prostate, renal or urothelial cell 
carcinoma. This clinical study will be composed of a Dose Finding Phase and an Expansion Phase. The Dose Finding Phase will estimate the Recommended Phase II Dose (RP2D)  in 
patients with advanced renal and urothelial cell carcinoma patients. The Dose Finding Phase will lead to the identification of an Expansion Test Dose for pembrol izumab  in combination 
with vorinostat. The Expansion Test Dose will be the Recommended Phase II Dose ( RP2D) 
(i.e. the highest tested dose that is declared safe and tolerable by the Investigators and Sponsor) . Patients will be treated with oral vorinostat e very day for 14 days, and with 
pembrolizumab  at the fixed dose of 200 mg 
IV. Each cycle is every 21 days. Two  dose 
levels of vorinostat will be tested in 2-patient 
cohorts according to the 3 + 3 standard design (100 mg and 200 mg).  200 mg dose represents 50% of the reco mmended 
vorinostat dose as singl e agent.  
For the Dose Finding Phase (Combination Phase, Schema A), the starting dose level of vorinostat will be 100 mg by mouth ( PO) 
every day for 14 days, with 7 days break. The first dose level will have a minimum of 3 patients treated (unless the first 2  patients 
experience DLTs  before the 3
rd patient is 
enrolled).   
Schema A: Combination Phase 
IUSCC-0551  
Version 04/07/2021 NCT #02619253 8 
 DLTs are defined as Grade ≥  3 hematologi cal/non hematological toxicities attributable to 
vorinostat and/or pembrolizumab  during the first 21  days of the combination treatment (days 
1-21). If DLTs occur in 1 patient treated at the starting dose level a minimum of another 
3 patients will be treate d at this dose level. If  a DLT occurs in more than 1 patient in the first 
6 patients the study will be terminated. If a DLT occur s in ≤ 1/6 patients , 3 additional 
patients will be treated at the next dose level (level  2) with 200  mg vorinostat PO. If no DLTs 
occur at dose level 2, this dose level will be recommended for the expansion cohorts of the study. Patients who experience Grade ≥  3 toxicity and r ecover to ≤  Grade  1 (or to 
pretreatment baseline level toxicity) may continue treatment at the next vorinostat lower 
level.  
 Once the RP2D is identified, the Dose Expansion Phase will be opened. During the Dose Expansion Phase, t he study will 
have a run-in phase with sequential single- agents (Schema B ) and then the 
combination phase (S chema  A). The run-
in phase may be waived at the investigator’s discretion. The reason for 
the run-in phase during dose expansion is to obtain data on the immunomodulatory effects of vorinostat separately from pembrolizumab . Forty -five patients with 
prior treatments will be enrolled in three  
expansion cohorts: 15 anti-PD1 naive renal and urothelial patients , 15 anti- PD1 resistant 
renal and urothelial patients (defined as patien ts with transient clinical response or without 
clinical response to prior immune -checkpoint inhibition) , and 15 patients with androgen-
sensitive or castration -resistant prostate cancer . The prostate cohort has been added in an 
amendment during the Dose Expansion Phase, and therefore, will not be par t of the Dose 
Finding P hase.  
Anti-tumor activity will be assessed by radiological tumor assessments conducted at baseline, 
12 weeks and every 6 weeks thereafter, using RECIST version 1.1 (see Section 14.3). RECIST 1.1 will be used for treatment decisions until first radiologic evidence of progressive 
disease (PD). Following the first evidence of radiologic PD, treatment decisions may be  made by the adaption of RECIST 1.1, termed the immune -related response cri teria (irRC) 
(see Section  14.6) to account for the tumor response patterns seen with pembrolizumab 
treatment (e.g. tumor flare ).  
1 Cycle  = 3 weeks  (21 days )  
Dose Level  Pembrolizumab  IV Q3W  Vorinostat PO QD x 14 days  
        1                200 mg 100 mg  
        2                200 mg 200 mg  Schema B: Run-In Phase 

IUSCC- 0551  
Version 04/07/2021 NCT #02619253 9 
 The RP2D is the dose of pembrolizumab  and vorinostat in combination chosen for further 
clinical development. Further experience in the Dose Expansion Cohort may result in a 
RP2D dose lower than the MTD . 
2.2 Trial Diagram  
 
3.0 OBJECTIVES  
3.1 Primary Objective  
To assess the early signals for anti -tumor a ctivity (i.e. objective response rate, 
progression- free survival) of pembrolizumab in combination with vorinostat in patients 
with advanced prostate, renal or urothelial cell carcinoma.  
3.2 Secondary Objectives  
• To evaluate the overall safety profile of pembrolizumab in combination with 
vorinostat.  
• To assess the safety and tolerability of pembrolizumab in combination with vorinostat in patients with advanced prostate,  renal or urothelial cell carcinoma in 
order to select the recommended Phase 2 D ose (RP2D ). 
3.3 Correlative Objective  
• To characterize immune cell subsets, and miRs in tumor and/or blood  
4.0 BACKGROUND & RATIONALE 
4.1 Background  
Refer to the Investigator’s Brochure (IB)/approved labeling for detailed background information on pembrolizumab  and vorinostat  (MK-3487) . 

IUSCC-0551  
Version 04/07/2021 NCT #02619253 10 
 4.1.1 Pharmaceutical and Therapeutic Background 
Blocking the PD -1/PD -L1 interaction is a novel immunotherapeutic approach for the treatment 
of solid tumors including renal cell carcinoma (RCC). PD -1 inhibition has shown single -agent 
activity in clear cell RCC patients whose disease has progr essed following VEGF pathway 
inhibitor therapy 1. Recent data have also shown a significant activity of an anti PD -L1 
antibody in urothelial cell carcinoma patients 2. Though this new class of agents represents a 
very promising therapeutic strategy only a fraction of patients seems to achieve durable 
responses.  
Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD -1 and its ligands, 
PD-L1 and PD -L2.  Keytruda
TM (pembrolizumab) has recently been approved in the United 
Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.  
Histone deacetylase ( HDAC) inhibitors induce acetylation of several histone and non-histone 
proteins, which contributes to a wide spectrum of anti -tumor and immunomodulatory activities 
of this class of agents. Pan HDAC inhibitors have shown eith er immunosuppressive or 
immunopromoting properties through modulating cytokine expression, affecting macrophage and dendritic cells, or regulating costimulation molecules. HDAC inhibitors have been also shown to induce activation of major histocompatibility complex (MHC) class I and class II 
proteins, and co- stimulatory molecules CD40, CD80 and CD86. The results from the clinical 
trials with HDAC inhibitors in cutaneous T -cell lymphoma and large cell lymphoma patients 
that had lead the approval of vorinostat and romidepsin suggest that the antitumor activity these agents may be in part due to the modulation of the immune response. O ur group has reported 
that the class I HDAC inhibitor entinostat suppresses regulatory T (Treg) cell function, enhances anti -tum or immune response and facilitates cytokine and vaccine immunotherapy in 
murine renal cell carcinoma and prostate cancer models, respectively 
3,4. This Treg suppression 
action does not seem  to be  through a depletion mechanism. On further analysis, we obser ved 
that entinostat suppresses Foxp3 gene expression in Treg cells and inhibits suppressive function of Treg cells. Entinostat acetylates STAT  3 leading to down regulation of Foxp3. Our 
preclinical data have shown the synergistic effect of entinostat in co mbination with high dose 
interleukin 2 in the RENCA model  
4. Based on these results, we have completed  a CTEP -
Figure 1. Modulation of Treg function with class -
specific HDAC inhibitors. Class I HDAC inhibitors induce acetylation of STAT3 by inhibiting HDAC3 or HDAC1, downregulate Foxp3 gene expressi
on and 
suppress Treg function. Class II HDAC inhibitor 
treatment induces Foxp3 hyperacetylation by targeting HDAC7 and HDAC 9, which leads to stabilization of 
Foxp3 protein and enhanced Treg function. SIRT 1 (Class 
III specific) inhibitor also induces hyperacetylation and stabilization of Foxp3 protein, and enhances the Treg 
function. A pan inhibitor may target Class I HDACs at a 
low dose and impair Treg function. At a higher dose, the pan inhibitor may target Class II HDAC and show a dominant Treg promoting effect
6). 
IUSCC- 0551  
Version 04/07/2021 NCT #02619253 11 
 sponsored phase I/II clinical trial with entinostat in combination with high dose interleukin 2 
in patients with RCC ([STUDY_ID_REMOVED]). The phase I re sults have been recently reported and 
suggest a biological and clinical activity of this combination 5. Our preliminary data also 
suggest that inhibitors able to modify Class I HDACs (Class I specific and pan) decreased Foxp3 levels in Tregs in a dose -depe ndent manner, whereas class II specific HDAC inhibitors 
did not affect Foxp3 levels. This observation suggests that only class I HDAC inhibition results 
in Treg suppression. In addition, we observed that in vivo  treatment with the pan HDAC 
inhibitor panobi nostat showed opposite effects when applied at different doses: low dose 
inhibited Tregs suppressive function whereas high dose treatment promoted Treg function 
6. 
Panoninostat has much higher affinity for class I HDACs than for class II HDACs 7. We 
hypothesize that pan HDAC inhibitors such as panobinostat and vorinostat primarily inhibit 
class I HDACs at low doses, which shows Treg suppressive effect similar to class I specific inhibitors. At a high dose, pan HDAC inhibitors saturate class I HDACs and targ ets class II, 
and the Treg -promoting effect resulting from class II HDACs inhibition becomes dominant.   
4.2 Rationale  
Novel strategies to enhance the antitumor activity of immune -checkpoint inhibitors are under 
development. This study will assess the immunomodulatory activity of vorinostat in patients receiving the PD1 inhibitor pembrolizumab. We have chosen two diseases (renal and urothelial cell carcinoma) that have been reported to respond to PD1/PD -L1 inhibition. We 
have also include a cohort of patients with prostate cancer as a recent report have shown activity of pembrolizumab after enzalutamide. However, as a proof of principle, we will include both hormone sensitive and castration resistant metastatic prostate  cancer 
8. The 
schedule of vorinostat is based on our previous experience with this drug. We have 
completed a CTEP -sponsored phase I/II clinical trial with vorinostat in combination with 
bevacizumab in patients with pretreated RCC patients ([STUDY_ID_REMOVED]). T he dose of 200 mg 
PO (twice a day) BID 14 days on, 7 days off every 21 days was relatively well tolerated9. 
Based on the hypothesis that low dose pan HDAC inhibitors will have a suppressive function 
on Tregs but not on T effector cells, the starting dose of vorinostat will be 100 mg and will be 
escalated up to 200 mg only rather than the 400 mg dose approved for the treatment of 
cutaneous T cell lymphomas.    
Based on our preclinical data, this study will test the following hypotheses:  
1. Class I HDAC inhibitio n by either selective Class I HDAC or low dose pan HDAC 
inhibitors may decrease Tregs and MDSCs without affecting T effector cells  
2. Vorinostat may enhance the anti -tumor activity of immune -check point inhibitors by 
suppressing inhibitory cells and inducing PDL -1/2 expression.  
3. Vorinostat may re -sensitize patient previously treated with immune -check point 
inhibitors.  
4.2.1 Rationale for Dose Selection/Regimen/Modification   
An open- label Phase I trial (Protocol 001) is being conducted to evaluate the safety and 
clinical activity of single agent pembrolizumab. The dose escalation portion of this trial 
IUSCC- 0551  
Version 04/07/2021 NCT #02619253 12 
 evaluated three dose levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, administered every 2 weeks 
(Q2W) in subjects with advanced solid tumors.  All three dose levels were well tolerated and no dose -limiting toxicities were observed.  This first in human study of pembrolizumab 
showed evidence of target engagement and objective evidence of t umor size reduction at all 
dose levels (1 mg/kg, 3 mg/kg and 10 mg/kg Q2W).  No MTD has been identified to date.  Recent data from other clinical studies within the pembrolizumab  program has shown that a 
lower dose of pembrolizumab  and a less frequent schedule may be sufficient for target 
engageme nt and clinical activity.  
 Pharmacokinetic ( PK) data analysis of pembrolizumab  administered Q2W and Q3W showed 
slow systemic clearance, limited volume of distribution, and a long half- life (refer to 
Investigator Brochure ).  Pharmacodynamic (PD) data (IL -2 release assay) suggested that 
peripheral target engagement is durable (>21 days).  This early PK and PD  data provides 
scientific rationale for testing a Q2W and Q3W dosing schedule.   
 A population pharmacokinetic analysis has been performed using serum concentration time data from 476 patients. Within the resulting population PK model, clearance and volume parameters of pembrolizumab  were found to be dependent on body weight. The relationship 
between clearance and body weight, with an allometric exponent of 0.59, is within the range 
observed for other antibodies and would support both body weight normalized dosing or a fixed dose across all body weights. P embrolizumab  has been found to have a wide 
therapeutic range based on the melanoma indication.  The differences in exposure for a 200 mg fixed dose regimen relative to a 2 mg/kg Q3W body weight based regimen are anticipated to remain well within the established exposure margins of 0.5 – 5.0 for  
pembrolizumab  in the melanoma indication. The exposure margins are based on the notion of 
similar efficacy and safety in melanoma at 10 mg/kg Q3W vs. the proposed dose regimen of 2 mg/kg Q3W (i.e. 5 -fold higher dose and exposure). The population PK evaluation revealed 
that there was no significant impact of tumor burden on exposure. In addition, exposure was similar between the non -small -cell lung carcinoma (NSCLC)  and melanoma indications. 
Therefore, there are no anticipated changes in exposure between different indica tion settings.  
 The rationale for further exploration of 2 mg/kg and comparable doses of pembrolizumab in solid tumors is based on: 1) similar efficacy and safety of pembrolizumab when dosed at either 2 mg/kg or 10 mg/kg Q3W in melanoma patients, 2) the flat exposure -response 
relationships of pembrolizumab for both efficacy and safety in the dose ranges of 2 mg/kg Q3W to 10 mg/kg Q3W, 3) the lack of effect of tumor burden or indication on distribution behavior of pembrolizumab (as assessed by the population PK model) and 4) the assumption that the dynamics of pembrolizumab target engagement will not vary meaningfully with tumor type.  
The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on simulations performed using the  population PK model of pembrolizumab showing that the 
fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as associated with maximal 
efficacy response and 3) will maintain individual patients exposure in the exposure range established in melanoma that are well tolerated and safe.  
IUSCC-0551  
Version 04/07/2021 NCT #02619253 13 
 The choice of the starting dose of vorinos tat (100 mg) is based on the preclinical data 
suggesting that low dose of pan HDAC inhibitors may have already positive 
immunomodulatory activity (see 4.1.1).   
5.0 METHODOLOGY  
5.1 Entry Criteria  
5.1.1 Subject Inclusion Criteria  
In order to be eligible for participation  in this trial, the subject must:  
1. Have one of the following diagnoses/conditions: 
a. Renal cell carcinoma - previously treated and progressive disease, locally 
advanced or metastatic  
b. Urothelial cell carcinoma - previously treated and progressive disease, locally 
advanced or metastatic  
c. Prostate cell carcinoma - progressive disease, locally advanced or metastatic 
disease (enrolling only at IUSCC and its affiliates). Patients with hormone -
sensitive disease where ADT in combination with either docetaxel or 
abiraterone is indicated will not be eligible (i.e. patients with high burden disease).  
2. Be willing and able to provide written informed consent for the trial.  
3. Be ≥  18 years of age on day of signing informed consent. 
4. Have measurable disease based on RECIST 1.1  (Section 14.3)
 for patients with solid 
malignancies or evaluable disease as assessed by bone scan and/or PET scan .  
Patients with advanced or metastatic prostate cancer  can have either androgen -
sensitive or castration -resistant disease.  
5. Have a performance status of 0 -2 on the ECOG Performance Scale (Section 14.1). 
6. Demonstrate adequate organ function as defined in Table 1.   
Table 1:  Adequate Organ Function Laboratory Values  
System  Laboratory Value  
Hematological   
Absolute neutrophil count (ANC)  ≥1,500 /mcL  
Platelets  ≥100,000 / mcL  
Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without transfusion or EPO 
dependency (within 7 days of assessment)  
Renal   
Serum creatinine OR 
Measured or calculateda creatinine clearance  ≤1.5 X upper limit of norm al (ULN) OR 
 
IUSCC-0551  
Version 04/07/2021 NCT #02619253 14 
 (GFR can also be used in place of creatinine or 
CrCl)  ≥60 mL/min for subject with creatinine levels > 1.5 X 
institutional ULN  
Hepatic   
Serum total bilirubin  ≤ 1.5 X ULN OR 
 Direct bilirubin ≤ ULN for subjects with total bilirubin 
levels > 1.5 ULN  
AST (SGOT) and ALT (SGPT)  ≤ 2.5 X ULN  OR 
≤ 5 X ULN for subjects with liver metastases  
Albumin  >2.5 mg/dL  
Coagulation  
International Normalized Ratio (INR) or 
Prothrombin Time (PT)  
 Activated Partial Thromboplastin Time (aPTT)  ≤1.5 X ULN unless subject is receiving anticoagulant 
therapy 
as long as PT or PTT is within therapeutic range of intended 
use of anticoagulants  
≤1.5 X ULN unless subject is receiving anticoagulant therapy 
as long as PT or PTT is within therapeutic range of intended 
use of anticoagulants  
aCreatinine clearance should be calculated per institutional standard.  
 
7. Female subject of childbearing potential (see appendix 14.6) should have a negative 
urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication.  If the urine test is positive or cannot be confirmed as negative, a 
serum pregnancy test will be required.   
8. Subjects of childbearing potential should be willing to use 2 methods of contraception for the course of the study through 120 days after the las t dose of study medication 
(reference Section 5. 5.2).  Acceptable methods of birth control include: abstinence, 
partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm o r cervical vault cap, 
or hormonal birth control (pills or injections).  NOTE: Females are considered of 
childbearing potential unless they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are 
postmenopausal ( a woman who is ≥  45 years of age and has not had menses for 
greater than 1 year ). 
9.  Male subjects without a previous vasectomy should agree to use an adequate method of contraception (i.e. abstinence, condom with sp ermicidal foam/gel/film/cream) 
starting with the first dose of study therapy through 120 days after the last dose of study therapy. 
10. Subjects with urothelial carcinoma must have received a prior platinum- based 
regimen in the metastatic setting or have signed consent for this study within 12 
months of receiving a platinum -based regimen in the perioperative setting 
(neoadjuvant or adjuvant).  
11. Subjects with a history of diabetes mellitus must have HgbA1c level of < 8.5% upon study entry. 
IUSCC- 0551  
Version 04/07/2021 NCT #02619253 15 
 5.1.2 Subject Exclusion Crite ria 
The subject must be excluded from participating in the trial if the subject:  
1. Is currently participating and receiving study therapy or has participated in a study of 
an investigational agent and received study therapy or used an investigational device 
within 4 weeks of the first dose of treatment.  
2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any 
other form of immunosuppressive therapy within 7 days prior to the first dose of trial 
treatment.   
3. Has active TB (Bacillus Tuberculosis)  
 
4. Hypersensitivity to pembrolizumab or any of its excipients.  
5. Has had a prior anti -cancer monoclonal antibody (mAb) within 4 weeks prior to 
Cycle 1  Day 1 or who has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse 
event s due to agents administered more than 4 weeks earlier.  
6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Cycle 1  Day 1 or who has not recovered (i.e . ≤ Grade 1 or at 
baseline) from adverse events due to a previously administered agent.  
- Note:  Subjects with ≤ Grade 2 neuropathy are an exception to this criterion 
and may qualify for the study. 
- Note:  If subject received major surgery, they must have recovered adequately from the toxicity and/or complica tions from the intervention prior to starting 
therapy.   
7. Has a known additional malignancy that is progressing or requires active treatment.  Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone pote ntially curative therapy or in situ cervical cancer.  
8. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.  Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four 
weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to  trial treatment.   This exception does not 
include carcinomatous meningitis which is excluded regardless of clinical stability.    
9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e .g. thyroxine, insulin, or 
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.  
IUSCC- 0551  
Version 04/07/2021 NCT #02619253 16 
 10. Has known history of, or any evidence of active, non- infectious pneumonitis.  
11. Has an active infection requiring systemic therapy.  
12. Has a history or current evidence of any condition, therapy, or laboratory abnormality 
that might confound the results of the trial, interfere  with the subject’s participation 
for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.   
13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.  
14. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre -screening or screening visit 
through 120 days after the last dose of  trial treatment.  
15. Has received prior therapy with an anti -PD-1, anti -PD-L1, or anti -PD-L2 agent  (only  
during Dose Expansion Phase for  Cohort A) . 
16. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).  
17. Has known active Hepatitis B (e.g.  HBsAg reactive) or Hepatitis C (e.g. HCV RNA 
[qualitative] is detected).  
18. Has received a live vaccine within 30 days of planned start of study therapy. 
5.2 Trial Treatments  
The treatment to be used in this trial is outlined below in Table 2 
Table 2:  Trial Treatment  
Drug  Dose/Potency  Dose 
Frequency  Route of 
Administration  Regimen/Treatment 
Period  Use 
Pembrolizumab  200 mg   Q3W  IV infusion  Day 1 of each 3 week 
cycle Experimental  
Vorinostat  100-200 mg  QD  oral Day 1 -14 of each 3 
week cycle  Experimental  
 Trial treatment should begin as close as possible to the date on which treatment is 
allocated/assigned.  
5.2.1 Dose Selection/Modification  
5.2.1.1 Dose Selection  
The rationale for selection of doses to be used in this trial is provided in Section 4.0 – Background &  Rationale.   
IUSCC-0551  
Version 04/07/2021 NCT #02619253 17 
 Details on preparation and administration of pembrolizumab ( MK-3475) are provided in the 
package insert .  
5.2.1.2 Dose Administration  
Treatment cycles consist of daily oral dosing of vorinostat (Days 1 through 14) and 
intravenous dosing of pembrolizumab (Day 1 , Cycle 1).  The two-drug regimen will be given 
every 3 weeks.  The starting dose of vorinostat will be 100 mg orally  QD per day for Days 1 
through 14.  The dose of pembrolizumab will be 200 mg  IV on Day 1, every 21 days.  
5.2.1.3 Definition of Dose -Limiting Toxicity (DLT)  
DLTs include any Grade 3 -5 toxicity related to vorinostat or pembrolizumab  during the 
combination phase only (Cycle 1) ( except for a ≥ Grade 3  decrease in lymphocytes). Grade 3 
nausea or vomiting should be considered a DLT only if unresponsive to therapy and ≥ 72 hours in duration.  Patients must have taken at least 4 of the 14 doses of vorinostat to be considered evaluable for DLT determination. Patients who do not complete the first cycle of combination therapy during the dose finding phase will be repla ced.  Patients who do not 
receive at least 75% of the expected dose of vorinostat due to toxicity are considered to have DLT.  Delay in treatment due to a toxicity greater than 2 weeks is also considered a DLT. 
ALT>3xULN + Total bilirubin >2xULN will be a DLT which results in permanent drug discontinuation. 
3 patients will be enrolled at dose level 1:  
• If 1 DLT occurs in the first 3 patients, expand dose level 1 to 6 patients.  
• If 0-1 DLT occur in 6 patients, expand to dose level 2.  
• If 1 DLT occurs in the first 3 patients, expand dose level 2 to 6 patients. 
• If ≥ 2 DLTs occur in the 3-6 patient cohort at dose level 2, the lower dose level will 
be considered the MDT.  
• If ≥ 2 DLTs occur in the 3-6 patient cohort at dose level 1, the study will be 
terminated.  
 
5.2.1.4 Supportive Care Guidelines  
Note: there is an overlap in potential toxicity related to diarrhea.  If the patient has diarrhea (loose stool) = Grade 2, follow the supportive care guidelines for 
Vorinostat below. If the patient has diarrhea (loose stool) ≥ Gra de 3, follow the supportive 
care guidelines for Vorinostat below.  
If a patient has colitis (diarrhea with abdominal pain, mucus or blood in stool) ≥ Grade 2, follow the supportive care guidelines for Pembrolizumab below.  
Vorinostat:  Because vorinostat’s dose limiting toxicities are anorexia, dehydration, diarrhea, 
and fatigue, patients should maintain adequate fluid and food intake.  Patients will be encouraged to seek a nutritional consult, if necessary.    
IUSCC-0551  
Version 04/07/2021 NCT #02619253 18 
 Treat diarrhea promptly with appropriate supportive care, including loperamide.  Instruct 
patients to begin taking loperamide at the first signs of: 
• Poorly formed or loose stool 
• Occurrence of more bowel movements than usual in one day, or 
• Unusually high volume of stool.   
Loperamide should be taken in the following manner: 4 mg at first onset of diarrhea, then 2 mg after each unformed stool.  Daily dose should not exceed 16 mg/day.  Loperamide should not be taken prophylactically.  Advise patients to drink plenty of clear fluids to help prevent dehydration caused by diarrhea.  Avoid loperamide if there is the presence of blood or mucus in the stool or if diarrhea is accompanied by fever.  If grade 3 or 4 diarrhea develops on loperamide, discont inue further treatment with vorinostat. 
Pembrolizumab:  Supportive care guidelines for pembrolizumab can be found in Appendix 
14.5.  
5.2.1.5 Duration of Therapy  
Patients may continue on therapy until one of the following criteria applies:  
• Disease progression  (with the exception of pseudoprogression as described in Section 
5.9), 
• Intercurrent illness that prevents further administration of treatment,  
• Unacceptable adverse event(s),  
• Patient decides to withdraw from the study, or  
• General or specific changes in the patient’s condition that renders the patient unacceptable for further treatment in the judgment of the investigator.  
5.2.1.6 Dose Modifications 
Vorinostat should be held when ≥ Grade 3 to 4 drug- related adverse experiences occur. After 
resolution of these adverse experiences to Grade 1 or less (or to  pretreatment baseline level of 
toxicity) treatment with vorinostat may continue at the next lower dose  (see 2.1). Once the 
dose has been reduced, patients must remain at the reduced dose for the remainder of the study.  
Patients may have their dose reduce d once before being removed from the trial. Patients may 
only have their dose reduced to dose level 1. If grade 3 or 4 diarrhea develops despite supportive care, patients will discontinue further treatment with vorinostat.  
Vorinostat in combination with ot her agents could cause an exacerbation of any adverse event 
currently known to be caused by the other agent, or the combination may result in events never previously associated with either agent. 
Please see tables below for a list of adverse events experie nced by patients who have been 
treated with vorinostat.  
IUSCC- 0551  
Version 04/07/2021 NCT #02619253 19 
  
 
 
  

IUSCC-0551  
Version 04/07/2021 NCT #02619253 20 
 Pembrolizumab:  
AEs associated with pembrolizumab exposure, including coadministration with additional compounds, may represent an immunologi c 
aetiology. These immune -related AEs (irAEs) may occur shortly after the first dose or several months after the last dose of 
pembr olizumab/combination treatment and may affect more than one body system simultaneously. Therefore, early recognition and 
initiation of treatment is critical to reduce complications.  Based on existing clinical study data, most irAEs were reversib le and c ould 
be managed with interruptions of pembrolizumab/combination treatment, administration of corticosteroids and/or other supportive care. 
For suspected irAEs, ensure adequate evaluation to confirm etiology or exclude other causes. Additional procedures or  tests such as 
bronchoscopy, endoscopy, skin biopsy may be included as part of the evaluation. Dose modification and toxicity management gui delines 
for irAEs associated with pembrolizumab/combination treatment are provided in Table 3. 
Attribution of Toxici ty: 
When study interventions are administered in combination, attribution of an adverse event to a single component is likely to be 
difficult.   Therefore, while the investigator may attribute a toxicity event to the combination, to vorinostat or to pembrolizumab alone, 
for adverse events listed in Table 3, both interventions must be held according to the criteria in Table 3 D ose Modification and Toxicity 
Management Guidelines for Immune- Related Adverse Events Associated with Pembrolizumab.  
Holding Study Interventions:  
When study interventions are administered in combination, if the AE is considered immune -related, both interventions should be held 
according to recommended dose modifications.  
Restarting Study Interventions:  
Participants may not have any dose modifications (no change in dose or schedule) of pembrolizumab in this study, as described in Table 
3. 
1. If the toxicity does not resolve or the criteria for resuming treatment are not met, the participant must be discontinued from all study 
interventions. 
IUSCC-0551  
Version 04/07/2021 NCT #02619253 21 
 2. If the toxicities do resolve and conditions are aligned with what is defined in Table 3, the combination of vorinostat and 
pembrolizumab may be restarted at the discretion of the investigator.  In these cases where the toxicity is attributed to  the combination 
or to vorinostat alone, re -initiation of pembrolizumab as a monotherapy may be considered at the principal investigator’s discretion.  
Pembr olizumab may be interrupted for situations other than treatment- related AEs such as medical / surgical events and/or unforeseen 
circumstances not related to study intervention . However, intervention is to be restarted  within 3 weeks of the originally sched uled dose 
and within 42 days of the previously administered dose, unless otherwise discussed with the Sponsor. The reason for study intervention 
interruption is to be documented in the patient's study record. 
 Table 3: Dose modification and toxicity management guidelines for immune -related AEs associated with pembrolizumab 
monotherapy and IO Combinations   
 
General instructions:  
1. Severe and life- threatening irAEs should be treated with IV corticosteroids followed by oral steroids. Other 
immunosuppressive treatment should begin if the irAEs are not controlled by corticosteroids. 
2. Study intervention must be permanently discontinued if the irAE does not resolve or the corticosteroid dose is not 
≤10 mg/day within 12 weeks of the last study intervention treatment.  
3. The corticosteroid taper should begin when the irAE is ≤ G rade 1 and continue at least 4 weeks.  
4. If study intervention has been withheld, study intervention may resume after the irAE decreased to ≤  Grade  1 after 
corticosteroid taper.  
irAEs  Toxicity 
Grade 
(CTCAE v5.0) Action With 
Pembrol izumab  Corticosteroid and/or O ther 
Therapies  Monitoring and Follow -up 
Pneumonitis  Grade 2  Withhold  •  Administer corticosteroids (initial 
dose of 1 to 2  mg/kg prednisone or 
equivalent) followed by taper  
•  Add prophylactic antibiotics for 
opportunistic infections  •  Monitor participants for signs and 
symptoms of pneumonitis  
•  Evaluate participants with suspected 
pneumonitis with radiographic imaging and 
initiate corticosteroid treatment  Recurrent 
Grade 2,  
Grade 3 or 4  Permanently 
discontinue  
IUSCC-0551  
Version 04/07/2021 NCT #02619253 22 
  
Diarrhea/Colit
is  Grade 2 or 3  Withhold  •  Administer corticosteroids (initial 
dose of 1 to 2  mg/kg prednisone or 
equivalent) followed by taper  
 •  Monitor participants for signs and 
symptoms of enterocolitis (ie, diarrhea, 
abdominal pain, blood or mucus in stool 
with or without fever) and of bowel 
perforation (ie, peritoneal signs and ileus)  
•  Participants with ≥Grade 2 diarrhea 
suspecting colitis should consider GI 
consultation and performing endoscopy to 
rule out colitis  
•  Participants with diarrhea/colitis should be 
advised to drink liberal quantities of clear 
fluids. If sufficient oral fluid intake is not 
feasible, fluid and electrolytes should be 
substituted via IV infusion  Recurrent 
Grade 3 or 
Grade 4  Permanently 
discontinue  
AST or ALT 
Elevation or 
Increased 
Bilirubin  Grade 2 a Withhold  •  Administer corticosteroids (initial 
dose of 0.5 to 1 mg/kg prednisone or 
equivalent) followed by taper  •  Monitor with liver function tests (consider 
weekly or more frequently until liver 
enzyme value returned to baseline or is 
stable)  Grade 3 b or 4 c Permanently 
discontinue  •  Administer corticosteroids (initial 
dose of 1 to 2  mg/kg prednisone or 
equivalent) followed by taper  
T1DM or 
Hyperglycemi
a New onset 
T1DM or  
Grade 3 or 4 
hyperglycemia 
associated Withhold d •  Initiate insulin replacement therapy 
for participants with T1DM •  Moni tor participants for hyperglycemia or 
other signs and symptoms of diabetes  
IUSCC-0551  
Version 04/07/2021 NCT #02619253 23 
 with evidence 
of β-cell 
failure •  Administer antihyperglycemic in 
participants with hyperglycemia  
 
Hypophysitis  Grade 2  Withhold  •  Administer corticosteroids and 
initiate hormonal  replacements as 
clinically indicated  •  Monitor for signs and symptoms of 
hypophysitis ( including  hypopituitarism 
and adrenal insufficiency)  Grade 3 or 4  Withhold or 
permanently 
discontinue d 
Hyperthyroidis
m Grade 2  Continue  •  Treat with nonselective beta-blockers 
(eg, propranolol) or thionamides as 
appropriate  •  Monitor for signs and symptoms  of thyroid 
disorders  
Grade 3 or 4  Withhold or 
permanently 
discontinue d 
Hypothyroidis
m Grade 2, 3  or 4 Continue  •  Initiate  thyroid replacement 
hormones (eg, levothyroxine or 
liothyronine) per standard of care  •  Monitor for signs and symptoms  of thyroid 
disorders  
Nephritis : 
grading 
according to 
increased 
creatinine or 
acute kidney 
injury  Grade 2  Withhold  •  Administer corticosteroids 
(prednisone 1  to 2 mg/kg or 
equivalent ) followed by taper  •  Monitor  changes of renal function  
Grade 3 or 4  Permanently 
discontinue  
Neurological 
Toxicities  Grade 2  Withhold  •  Based on severity of AE administer 
corticosteroids •  Ensure  adequate evaluation to confirm 
etiology and/or exclude other causes  
Grade 3 or 4  Permanently 
discontinue  
Myocarditis  Grade 1  Withhold  
IUSCC-0551  
Version 04/07/2021 NCT #02619253 24 
 Grade 2, 3 or 4  Permanently 
discontinue  •  Based on severity of AE administer 
corticosteroids •  Ensure  adequate evaluation to confirm 
etiology and/or exclude other causes  
 
Exfoliative 
Dermatologic 
Conditions  Suspected 
SJS, TEN, or 
DRESS  Withhold  •  Based on severity of AE administer 
corticosteroids •  Ensure  adequate evaluation to confirm 
etiology or exclude other causes  
Confirmed 
SJS, TEN, or 
DRESS  Permanently 
discontinue  
All Other 
irAEs  Persistent  Grade  
2 Withhold  •  Based on severity of AE administer 
corticosteroids •  Ensure adequate evaluation  to confirm 
etiology or exclude other causes  
Grade 3  Withhold or 
discontinue 
based on the 
event e  
Recurrent 
Grade 3 or 
Grade 4  Permanently 
discontinue  
AE(s)=adverse event(s); ALT= alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for 
Adverse Events; DRESS=Drug Rash with Eosinophilia and Systemic Symptom; GI=gastrointestinal; IO=immuno -oncology; ir=immune 
related;  IV=intravenous; SJS=Stevens-Johnson Syndrome; T1DM=type 1 diabetes mellitus; TEN=Toxic Epidermal Necrolysis; 
ULN=upper limit of normal. 
Note: Non -irAE will be managed as appropriate, following clinical practice recommendations. 
a AST/ALT: >3.0  to5.0 x  ULN if baseline normal; >3.0  to 5.0 x baseline, if baseline abnormal;  
bilirubin:>1.5  to 3.0 x ULN if baseline normal; >1.5 to 3.0 x baseline if baseline abnormal  
b AST/ALT: >5.0 to 20.0 x ULN, if baseline normal; >5.0  to 20.0 x baseline, if baseline abnormal; bilirubin:>3.0  to 10.0 x ULN if baseline 
normal; >3.0 to 10.0 x baseline if baseline abnormal  
c AST/ALT: >20.0 x ULN, if baseline normal; >20.0 x baseline, if baseline abnormal;  
bilirubin:  >10.0  x ULN if baseline normal; >10.0 x baseline if baseline abnormal  
IUSCC-0551  
Version 04/07/2021 NCT #02619253 25 
 d The decision to withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physic ian. If control 
achieved or ≤  Grade 2, pembrolizumab may be resumed.  
e Even ts that require discontinuation include, but are not limited to: encephalitis and other clinically important irAEs. 
 
 
Dose modification and toxicity management of infusion -reactions related to pembrolizumab  
Pembrolizumab may cause severe or life- threatening infusion -reactions including severe hypersensitivity or anaphylaxis. 
Signs and symptoms usually develop during or shortly after drug infusion and generally resolve completely within 24 
hours of completion of infusion. Dose modification and toxicity management guidelines on pembrolizumab associated infusion reaction are provided i n Table 4.  
Table 4 Pembrolizumab Infusion Reaction Dose modification an d Treatment Guidelines  
NCI CTCAE Grade  Treatment  Premedication at Subsequent 
Dosing  
Grade 1  
Mild reaction; infusion 
interruption not indicated; 
intervention not indicated  Increase monitoring of vital signs as medically indicated until the 
participant is deemed medically stable in the opinion of the investigator.  None  
Grade 2  
Requires therapy or infusion interruption but responds promptly to 
symptomatic treatment 
(e.g., antihistamines, NSAIDs, narcotics, IV fluids); prophylactic medications indicated for ≤24 hrs  Stop Infusion.  
Additional appropriate medical therapy may include but is not limited to: IV fluids 
Antihistamines  
NSAIDs  
Acetaminophen  
Narcotics  
Increase monitoring of vital signs as medically indicated until the 
participa nt is deemed medically stable in the opinion of the 
investigator.  
If symptoms resolve within 1 hour of stopping drug infusion, the infusion may be restarted at 50% of the original infusion rate (e.g. 
from 100 mL/hr to 50 mL/hr).  Otherwise dosing will be held until Participant may be premedicated 
1.5h (± 30 minutes) prior to infusion of study intervention with:  
Diphenhydramine 50 mg po (or 
equivalent dose of antihistamine).  
Acetaminophen 500-1000 mg po 
(or equivalent dose of analgesic).  
IUSCC- 0551  
Version 04/07/2021 NCT #02619253 26 
 symptoms resolve and the participant should be premedica ted for 
the next scheduled dose.  
Participants who develop Grade 2 toxicity despite adequate 
premedication should be permanently discontinued from 
further study drug intervention  
Grades 3 or 4  
Grade 3:  
Prolonged (i.e., not rapidly 
responsive to symptomatic medication and/or brief 
interruption of infusion); 
recurrence of symptoms following initial 
improvement; 
hospitalization indicated for other clinical sequelae (e.g., 
renal impairment, 
pulmonary infiltrates)  
Grade 4:  
Life-threatening; pressor or 
ventilatory support 
indicated  Stop Infus ion. 
Additional appropriate medical therapy may include but is not 
limited to: 
Epinephrine** IV fluids  
Antihistamines  
NSAIDs  
Acetaminophen  
Narcotics  
Oxygen  
Pressors  
Corticosteroids  
Increase monitoring of vital signs as medically indicated until the 
participant is deemed medically stable in the opinion of the 
investigator.  
Hospitalization may be indicated.  
**In cases of anaphylaxis, epinephrine should be used immediately.  
Participant is permanently discontinued from further study 
drug intervention.  No subsequent dosing  
Appropriate resuscitation equipment should be available at the bedside and a physician readily available during the period of  drug 
administration.  
For further information, please refer to the Common Terminology Criteria for Adverse Events v5.0 (CTCAE) at http://ctep.cancer.gov  
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 27 
 5.2.1.6 Timing of Dose Administration  
Trial treatment should be administered on Day 1 of each cycle after all 
procedures/assessments have been completed as detailed on the Schedule of Assessments (Section 6.0).  Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.  
All trial treatments will be administered on an outpatient basis.  
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.  Sites should make every effort to target infusion timing to be as close to 30 minutes as 
possible.  However, given the variability of infusion pumps from site to site, a window of - 5 
minutes and +10 minutes is permitted (i.e. infusion time is 30 minutes: -5 min/+10 min). 
The package insert  contains specific inst ructions for the preparation of the pembrolizumab 
infusion fluid and administration of infusion solution.  
Patients should store  vorinostat capsules at room temperature, 15 to 30 ºC (59 to 86 ºF).   Do not 
store above 30
0C. Avoid exposure to excessive moisture. Vorinostat capsules must be 
administered whole. Administer doses of vorinostat with food if possible.  Vorinostat capsule 
should be administered according to the package insert.  
5.2.2 Trial Blinding/Masking  
This is an open -label trial; therefore, the Sponsor, investigator and subject will know the 
treatment administered.  
5.3 Concomitant Medications/Vaccinations (allowed & prohibited)  
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during the ongoing trial.  If there is a clinical indication for one of these or other medications or vaccinations specifically prohibited during the trial, discontinuation from trial therapy or vaccination may be required.  The investigator should discuss any questions regarding this with the Sponsor who will discuss this with the Merck C linical team.  The final decision on 
any supportive therapy or va ccination rests with the investigator and/or the subject's primary 
physician.  
5.3.1 Acceptable Concomitant Medications 
All treatments that the investigator considers necessary for a subject’s welfare may be administered at the discretion of the investigator in keeping with the community standards of medical care.  All concomitant medication will be recorded on the case report form (CRF) including all prescription, over -the-counter (OTC), herbal supplements, and IV medications 
and fluids.  If changes occur during the trial period, documentation of drug dosage, 
frequency, route, and date may also be included on the CRF. 
All concomitant medications received within 28 days before written informed consent and 30 
days after the treatment discontinuation should be recor ded.  Concomitant medications 
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 28 
 administered after 30 days after treatment discontinuation should be recorded for SAEs and 
ECIs as defined in Section 7.2. 
5.3.2 Prohibited Concomitant Medications  
Subjects are prohibited from receiving the following therapies durin g the Screening and 
Treatment Phase (including retreatment for post- complete response relapse) of this trial:  
• Antineoplastic systemic chemotherapy or biological therapy  
• Immunotherapy not specified in this protocol  
• Chemotherapy not specified in this protoc ol 
• Investigational agents other than pembrolizumab and vorinostat  
• Radiation therapy   
o Note:  Radiation therapy to a symptomatic solitary lesion or to the brain may 
be allowed at the investigator’s discretion  with written Sponsor approval .   
• Live vaccines wi thin 30 days prior to the first dose of trial treatment and while 
participating in the trial.   Examples of live vaccines include, but are not limited to, the 
following: measles, mumps, rubella, varicella/zoster , yellow fever, rabies, Bacillus 
Calmette -Guérin , and typhoid vaccine.  
• Systemic glucocorticoids for any purpose other than to modulate symptoms from an event of clinical interest of suspected immunologic etiology.  The use of physiologic doses of corticosteroids may be approved after con sultation with the Sponsor.  
Subjects who, in the assessment by the investigator, require the use of any of the aforementioned treatments for clinical management should be removed from the trial.  Subjects may receive other medications that the investigator  deems to be medically 
necessary.  
The Exclusion Criteria describes other medications which are prohibited in this trial.  
There are no prohibited therapies during the Post -Treatment Follow -up Phase.  
5.4 Rescue Medications & Supportive Care 
Subjects should recei ve appropriate supportive care measures as deemed necessary by the 
treating investigator.  Suggested supportive care measures for the management of adverse events with potential immunologic etiology for pembrolizumab are outlined in section 5.2.1.6 of the protocol and in section 6.4.1 of the Investigator’s Brochure. Where appropriate, these guidelines include the use of oral or intravenous treatment with corticosteroids as well as additional anti -inflammatory agents if symptoms do not improve with administr ation of 
corticosteroids.  Note that several courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is decreased. For each disorder, attempts should be made to rule out other causes such as metastatic disease or bacterial  or viral infection, which might 
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 29 
 require additional supportive care. The treatment guidelines are intended to be applied when 
the investigator determines the events to be related to pembrolizumab.  
Note: if after the evaluation the event is determined not to be related, the investigator is instructed to follow the Investigator’s Brochure  but does not need to follow the treatment 
guidance (as outlined in the Investigator’s Brochure ). Refer to Section 5.2.1.6 for dose 
modification s.  
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin photography as part of evaluation of the event. Suggested conditional procedures, as appropriate, can be found in the Investigator’s Brochure . 
5.5 Diet/Activity/Other Considerations  
5.5.1 Diet 
Subjects should maintain a normal diet unless modifications are required to manage an AE such as diarrhea, nausea or vomiting.  
5.5.2 Contraception  
Pembrolizumab  and vorinostat may have adverse effects on a fetus in utero.  Furthermore, it 
is not known if pembrolizumab or vorinostat  have transient adverse effects on the 
composition of sperm.  Non-pregnant, non- breast -feeding women may be enrolled if they are 
willing to use 2 meth ods of birth control or are considered highly unlikely to conceive.  
Highly unlikely to conceive is defined as 1) surgically steriliz ed (they have undergone a 
hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or 2) postmenopausal (a woman  who is ≥45 years of age and has not had menses for greater than 1 year will be 
considered postmenopausal), or 3) not heterosexually active for the duration of the study. Acceptable methods of birth control include: abstinence, partner with previous vasect omy, 
placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control 
(pills or injections).  Subjects should start using birth control from written  informed conse nt 
throughout the study period up to 120 days after the last dose of study therapy.  
Male subjects without a previous vasectomy should agree to use an adequate method of 
contraception (i.e. abstinence, condom with spermicidal foam/gel/film/cream) starting with 
the first dose of study therapy through 120 days after the last dose of study therapy.  
Subjects should be informed that taking the study medication may involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study.  In order to participate in the study they must adhere  to the contraception requirement (described above) for the 
duration of  the study and during the  follow -up period defined in section 7.2.3- Pregnancy and 
Lactation . If there is any question that a subject will not reliably comply with the 
requirements for contraception, that subject should not be entered into the study.  
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 30 
 5.5.3 Use in Pregnancy  
If a subject inadvertently becomes pregnant while on treatment with pembrolizumab and/or 
vorinostat , the subject will immediately be removed from the study.  The site will contact the 
subject at least monthly and document the subject’s status until the pregnancy has been 
completed or terminated.  The outcome of the pregnancy will be reported to the Sponsor and to Merck without delay and within 24 hours  to the Sponsor and within 2 working days to 
Merck  if the outcome is a serious adverse experience (e.g. death, abortion, congenital 
anomaly, or other disabling or life -threatening complication to the mo ther or newborn).   
The study investigator will make every effort to obtain permission to follow the outcome of the pregnancy and report the condition of the fetus or newborn to the Sponsor. If a male subject impregnates his female partner the study person nel at the site must be informed 
immediately and the pregnancy reported to the Sponsor and to Merck and followed as described above and in Section 7.2.3.  
5.5.4 Use in Nursing Women  
It is unknown whether pembrolizumab  or vorinostat are  excreted in human milk.  Si nce many 
drugs are excreted in human milk, and because of the potential for serious adverse reactions in the nursing infant, subjects who are breast -feeding are not eligible for enrollment.  
5.6 Subject Withdrawal/Discontinuation Criteria  
Subjects may withdraw consent at any time for any reason or be removed  from the trial at the 
discretion of the investigator should any untoward effect occur.  In addition, a subject may be 
withdrawn by the investigator or the Sponsor if enrollment into the  trial is inappropriate, the 
trial plan is violated, or for administrative and/or other safety reasons.  If a subject withdraws 
from the study, they will no longer receive study intervention or be fol lowed at scheduled 
protocol visits.   Specific details reg arding discontinuation or withdrawal are provided in 
Section 7.1.4.1. 
A subject must be discontinued from the trial for any of the following reasons:  
• The subject or legal representative (such as a parent or legal guardian) withdraws 
consent.  
• Confirmed radi ographic disease progression  (with the exception of pseudoprogression 
as described in Section 5.9)  
• Any progression or recurrence of any malignancy, or any occurrence of another 
malignancy that requires active treatment  
• Unacceptable adverse experiences as d escribed in Section 5.2.1.7 
• Intercurrent illness that prevents further administration of treatment  
• Investigator’s decision to withdraw the subject  
• The subject has a confirmed positive serum pregnancy test  
• Noncompliance with trial treatment or procedure requirements 
• The subject is lost to follow -up 
• Completed 24 months of uninterrupted treatment with pembrolizumab  or 35 
administrations of study medication, whichever is later.  
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 31 
 Note: 24 months of study medication is calculated from the date of firs t dose. Subjects 
who stop pembrolizumab after 24 months may be eligible for up to one year of 
additional study treatment if they progress after stopping study treatment provided they meet the requirements detailed in Section 7.1.6.4 
• Administrative reasons  
 
The End of Treatment and Follow -up visit procedures are listed in Section 6 ( Schedule of 
Assessments ) and Section 7.1.6 ( Follow -up Requirements ).  After the end of treatment, each 
subject will be followed for 30 days for adverse eve nt monitoring (serious adverse events 
will be collected for 90 days after the end of treatment as described in Section 7.2).  Subjects who discontinue for reasons other than progressive disease will have post -treatment follow -
up for disease status until di sease progression, initiating a non -study cancer treatment, 
withdrawing consent or becoming lost to follow -up.  After documented disease progression, 
each subject will be followed by telephone for overall survival until death, withdrawal of consent, or the  end of the study, whichever occurs first . 
5.7 Discontinuation of Study Therapy after CR  
Discontinuation of treatment may be considered for subjects who have attained a confirmed CR that have been treated for at least 24 weeks with combination vorinostat and pembrolizumab and had at least two treatments with vorinostat and pembrolizumab beyond the date when the initial CR was declared.  Subjects who then experience radiographic disease progression may be eligible for up to one year of additional treatment with  vorinostat 
and pembrolizumab via the Retreatment  Phase at the discretion of the investigator if no 
cancer treatment was administered since the last dose of vorinostat and pembrolizumab, the 
subject meets the safety parameters listed in the Inclusion/Exclu sion criteria, and the trial is 
open.  Subjects will resume therapy at the same dose and schedule at the time of initial discontinuation.  Additional details are provided in Section 7.1.6.4. 
5.8 Subject Replacement Strategy  
Patients who do not complete the  first cycle of combination therapy during the dose finding 
phase  will be replaced. Patients who cannot complete Cycle 1 of the expansion phase for 
reasons unrelated to the study drug will also be replaced.  
5.9 Pseudoprogression  
For a clinically stable subject with first radiologic evidence of progressive disease ( PD), it is 
at the discretion of the site investigator to continue treating the subject with pembrolizumab 
until PD is confirmed at least 6 weeks from the date of the fir st tumor imaging suggesting 
PD. If radiologic PD is confirmed by the subsequent tumor imaging the subject should be discontinued from treatment unless, in the opinion of the investigator, the subject is achieving a clinically meaningful benefit.  
5.10 Clinical C riteria for Early Trial Termination  
Early trial termination will be the result of the criteria specified below:  
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 32 
 1. Quality or quantity of data recording is inaccurate or incomplete  
2. Poor adherence to protocol and regulatory requirements  
3. Incidence or severity of adverse drug reaction in this or other studies indicates a potential 
health hazard to subjects  
4. Plans to modify or discontinue the development of the study drug  
In the event of Merck decision to no longer supply study drug, ample notification w ill be 
provided so that appropriate adjustments to subject treatment can be made.  
 
      IUSCC-0551  
Version 04/07/2021 NCT #02619253 33 
 6.0 SCHEDULE OF ASSESSMENTS  
 
Trial Period:  Screening 
Phase  Run-in 
Phase13 Combination Phase  End of 
Treatment Post-Treatment 
Treatment Cycle  Screening1 
(Visit 1) -2 -1 1 1 
 
 
D 14  2 
 3 
 4 
 To be repeated beyond 8 
cycles  Discon tinua
tion Safety 
Follow-up2 Follow-up 
Visits3 Sur-
vival 
Follow-
up 
   5 6 7 8     
Scheduling Window  (Days): -28 days to 
start of 
first cycle  ±  
3 ±  
3 ±  
3 ±  
3 ±  
3 ±  
3 ±  
3 ± 
3 ±  
3 ± 
3 ±  
3 ±  
3 30 days post 
discon ± 3 Per institu -
tional 
guidelines Every 6 
months 
± 30 
Administrative Procedures   
Informed Consent  x                
Inclusion/Exclusion Criteria  x                
Demographics and Medical History  x                
Registration  x                
Prior and Concomitant Medication Review  x                
Trial Treatment Administration   x x x x x x x x x x x     
Post-study anticancer therapy status              x x x x 
Survival Status                 x 
Clinical Procedures/Assessments   
Review Adverse Events    x x  x x x x x x x x x   
Full Physical Examination4 x x x x  x x x x x x x x    
Drug Compliance Review    x  x x x x x x x x x    
Vital Signs , Weight  and Height (Screening 
Only) x x x x  x x x x x x x x    
ECOG Performance Status  X x x x  x x x x x x x x    
Laboratory Procedures/Assessments9  
      IUSCC-0551  
Version 04/07/2021 NCT #02619253 34 
 Trial Period:  Screening 
Phase  Run-in 
Phase13 Combination Phase  End of 
Treatment Post-Treatment 
Treatment Cycle  Screening1 
(Visit 1) -2 -1 1 1 
 
 
D 14  2 
 3 
 4 
 To be repeated beyond 8 
cycles  Discon tinua
tion Safety 
Follow-up2 Follow-up 
Visits3 Sur-
vival 
Follow-
up 
   5 6 7 8     
Scheduling Window  (Days): -28 days to 
start of 
first cycle  ±  
3 ±  
3 ±  
3 ±  
3 ±  
3 ±  
3 ±  
3 ± 
3 ±  
3 ± 
3 ±  
3 ±  
3 30 days post 
discon ± 3 Per institu -
tional 
guidelines Every 6 
months 
± 30 
Pregnancy Test – Urine or Serum β-HCG  x 5   x 5 x 5    
PT/INR and aPTT  x                
CBC with Differential  x x x x x x x x x x x x x    
Comprehensive Serum Chemistry Panel  x x x x  x x x x x x x x    
Urinalysis  x  x   x  x  x  x x    
T3, FT4 and TSH  x  x   x  x  x  x x    
HgbA1c11 x x x x  x x x x x x x     
Prostate Specific Antigen Test     x   x  x  x  x     
Efficacy Measurements   
Tumor Imaging  – CT16 x      x13   x16   x12  x 6  
Tumor Imaging - Bone Scan  x   
   x12, 
13   
x12,16  
 x12    
Tumor Imaging - 68Ga-PSMA -11 PET  
Scan17 x   
    x17         
Tumor Biopsies/Archival Tissue 
Collection/Correlative Studies Blood   
Archival (when available), Newly Obtained 
Tissue Collection  (optional) 7 x    x15            
Correlative Studies Blood Collection  x X8  x  x  x  x  x x 10    
  
      IUSCC-0551  
Version 04/07/2021 NCT #02619253 35 
 Footnotes:  
1 Procedures completed prior to consenting that are a part of a subject’s standard of care may be used if they fall within the 28 day window to start 
treatment.  Screening procedures completed 7 days of C1D1 do not need to be repeated.  
2 If the subject discontinues treatment due to disease progression, a phone call to the patient can serve as the S afety F ollow -up Visit if the End of 
Treatment V isit was done. If a subject initiates a new anti -cancer therapy within 30 days after the treatment discontinuation , the 30 day Safety 
Follow -up Visit must occur before the first dose of the new therapy.  Once new ant i-cancer therapy has been initiated the subject will move into 
Survival Follow -up. 
3 Applies to subjects who discontinue trial treatment for a reason other than disease progression. Subjects should be assessed per institutional 
guidelines  by radiologic imaging to m onitor disease status. Every effort should be made to collect information regarding disease status until the 
start of new anti -neoplastic therapy, disease progression, death, end of the study or if the subject begins retreatment with pembrolizumab . 
4 Full physical exams may also be done by the investigator or qualified designee throughout participation in the trial as clini cally indicated.  
5 Only if clinically indicated  and must be completed ≤ 7 days prior to the first dose of study medication  
6 It is recommended that after 1 year, imag ing should be done  every 6 months ± 2 weeks; however, institutional guidelines and investigator 
discretion may vary.  
7 Whenever possible, archival tissue from a tumor lesion  will be obtained at screening. However, p atients will be given the option to consent to a 
biopsy during the screening phase  in case archival tissue cannot be retrieved  and a second biopsy on Cycle 1 Day 14 ( - 3 days).  Missed tissue 
collection will not be considered a protocol deviation for the purposes of this study, as tissue collection is an exploratory  objective for this study.  
8 Run-in Phase, Cycle -2 Days 1 and 14  
9 Laboratory tests for screening or entry into the Retreatment  Phase should be performed within 10 days prior to the first dose of treatment.  After 
Cycle 1, pre -dose laboratory procedures can be conducted up to 72 hours prior to dosing.  Results must be reviewed by the investigator or 
qualified designee and found to be acceptable prior to each dose of trial treatment.  
10 When patients are taken off treatment and at the time of disease progression blood for correlative markers will be also obtai ned.   
11 HcbA1c only required for patients with diabetes mellitus at  time of  study entry.  
12 Only as clinically indicated  (Cohort A and B) .  Standard of care after initial 68Ga-PSMA -11 PET (Cohort C)  
13 Imaging will be done prior to dosing on C3D1.  
14 The run-in phase will only be done during the Dose Expansion Phase  and may be waived at the investigator’s discretion.  
15 Window for second biopsy is -3 days not +/ - 3 days as is the case for other procedures at this time point.  Biopsy should occur approximat ely 2 
hours following the most recent dose of vorinostat on cycle 1 day 14.  To ensure that these samples are obtained at the correct time, patients are 
urged to take their vorinostat dose in the clinic on the day of on-treatment sample collection.  
16 Imagi ng will be done every 3 cycles beginning cycle 6 throughout treatment.  
17 Applicable to a subset of patients in Cohort C (prostate cancer) only, as determined by the Principal  Investigator . The Ga-PSMA -11 PET scan 
should be completed at 12 weeks (C4D1)   
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 36 
 7.0 TRIAL PROCEDURES  
7.1 Trial Procedures 
The Schedule of Assessments -Section 6.0 summarizes the trial procedures to be performed 
at each visit.  Individual trial procedures are described in detail bel ow.  It may be necessary 
to perform these procedures at unscheduled time points if deemed clinically necessary by the 
investigator.  
Furthermore, additional evaluations/testing may be deemed necessary by the Sponsor  and/or 
Merck for reasons related to subje ct safety. In some cases, such evaluation/testing may be 
potentially sensitive in nature (e.g. HIV, Hepatitis C, etc.), and thus local regulations may require that additional informed consent be obtained from the subject.  In these cases, such evaluations/ testing will be performed in accordance with those regulations.  
7.1.1 Administrative Procedures 
7.1.1.1 Informed Consent  
The Investigator must obtain documented consent from each potential subject prior to participating in a clinical trial.  
Consent must be documented by the subject’s dated signature or by the subject’s legally acceptable representative’s dated signature on a consent form along with the dated signature of the person conducting the consent discussion.  
A copy of the signed and dated consent form should be given to the subject before participation in the trial.  
The initial informed consent form, any subsequent revised written informed consent form and any written information provided to the subject must receive the IRB’s approval  in 
advance of use.  The subject or his/her legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the subject’s willingness to continue participation in the trial.  The communic ation of this 
information will be provided and documented via a revised consent form or addendum to the original consent form that captures the subject’s dated signature or by the subject’s legally acceptable representative’s dated signature if the new information would affect the subject’s 
willingness to continue participation in the study as determined  by the IRB . 
Specifics about a trial and the trial population will be added to the consent form template at the protocol level.   
The informed consent will adhere to IRB requirements, applicable laws and regulations and Sponsor requirements.  
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 37 
 7.1.1.2 Inclusion/Exclusion Criteria  
All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee 
to ensure that the subject qualifies for the trial.  
7.1.1.3 Medical History  
A medical history will be obtained by the investigator or qualified designee  during the 
screening period.  Medical history will include all active conditions, and any condition diagnosed within the prior 10 years that are considered to be clinically significant by the Investigator.  Details regarding the disease for which the subject has enrolled in this study will be recorded separately and not listed as medical history.   
7.1.1.4 Prior and Concomitant Medications Review  
7.1.1.4.1 Prior Medications  
During the screening period, t he investigator or qualified designee will review prior 
medication use, including any protocol -specified washout requirement, and record prior 
medication taken by the subject within 28 days before written informed consent .  Tre atment 
for the disease for which the subject has enrolled in this study will be recorded separately and not listed as a prior medication.  
7.1.1.4.2 Concomitant Medications  
The investigator or qualified designee will record medication, if any, taken by the subject 
during the trial.  All medications related to reportable SAEs and event s of clinical interest 
(ECIs ) should be recorded as defined in Section 7.2. 
7.1.1.5 Disease Details and Treatments  
7.1.1.5.1 Disease Details  
The investigator or qualified designee will obtain prior and current details regarding disease 
status.   
7.1.1.5.2 Prior Treatment Details 
The investigator or qualified designee will review all prior cancer treatments including systemic treatments, radiation and surgeries.  
7.1.1.5.3 Subsequent Anti -Cancer Therapy Status  
The investigator  or qualified designee will review all new anti- neoplastic therapy initiated 
after the treatment discontinuation .  If a subject  initiates a new anti -cancer  therapy within 30 
days after treatment discontinuation, the 30 day Safety Follow -up V isit must occur before the 
first dose of the new therapy.  Once new  anti-cancer  therapy has been initiated the subject 
will move into S urvival Follow -up.  
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 38 
 7.1.1.6 Assignment of Screening and R egistration  Number  
Subjects will be assigned a screening  and registration  number in sequential order by the 
Coordinating Center’s study coordinator, or for participating sites, the Multicenter Network 
Administrator, or designee. Additional details of this process can be found in the Study Procedures Manual.  
7.1.1.7 Trial Compliance (Med ication/Diet/Activity/Other)  
Subjects will be given a drug diary (Section 14.4) to record doses of vorinostat and any 
adverse events he or she may experience. Drug diaries will be collected at the start of the next cycle , or at the time of the next clinic visit, whichever is sooner . Any discrepancies in 
drug accountability will be clarified with the subject.  
7.1.2 Clinical Procedures/Assessments  
7.1.2.1 Adverse Event (AE) Monitoring  
The investigator or qualified designee will assess each subject to evaluate for po tential new 
or worsening AEs as specified in the Schedule of Assessments and more frequently if clinically indicated.  Adverse events  will be graded and recorded throughout the study and 
during the follow -up period according to NCI CTCAE Version 4.0 ( reference Section 14.2).  
Toxicities will be characterized in terms regarding seriousness, causality, toxicity grading, and action taken with regard to trial treatment.  
All AEs of unknown etiology associated with pembrolizumab exposure should be evaluated 
to determine if it is possibly an Event of Clinical Interest (ECI ) of a potentially immunologic 
etiology (termed immune -related adverse events, or irAEs); see the separate package insert  
regarding the identification, evaluation and management of potential  irAEs.  Detailed 
information regarding ECIs can be found in Section 14.5.   
Please refer to Section 7.2 for detailed information regarding the assessment and recording of 
AEs.   7.1.2.2 Full Physical Exam  
The investigator or qualified designee will perform a complete physical exam during the 
screening period.  Clinically significant abnormal findings should be recorded as medical history.  Full physical exams may also be done by the investigator or qualified designee throughout participation in the trial as clinica lly indicated and as specified in the Schedule 
of Assessments (section 6.0.)   After the first dose of study intervention, new clinically 
significant abnormal findings should be recorded as AEs.   
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
 
    
  IUSCC-0551  
Version 04/07/2021 NCT #02619253 39 
 7.1.2.3 Vital Signs  
The investigator or qua lified designee will take vital signs at screening, prior to the 
administration of each dose of trial treatment and at treatment discontinuation as specified in 
the Schedule of Assessments (Section 6.0).  Vital signs should include temperature, pulse, respiratory rate, weight and blood pressure.  Height will be measured at screening only. 
7.1.2.4 Eastern Cooperative Oncology Group (ECOG) Performance Scale 
The investigator or qualified designee will assess ECOG status (see Section 14.1) at screening, prior to the ad ministration of each dose of trial treatment and discontinuation of 
trial treatment as specified in the Schedule of Assessments.   
7.1.2.5 Tumor Imaging and Assessment of Disease  
Imaging studies (CT and bone scan) will be performed at baseline, before Cycle 3, every 3 
cycles thereafter and at treatment discontinuation  as described in Section 7.1.4.1 below.  CT 
modalities should be done according to standard of care for the patient ’s disease. Bone scans 
should be done at baseline and then only as clinically indicated.  
Patients in Cohort C (prostate) will have two PET scans using 
68Ga-PSMA -11: once at baseline 
and then at 12 weeks ( Cycle 4) Not all patients in Cohort C will have the additional PET scans. 
This determination will be made by the Principal Invest igator.  
Participant eligibility will be determined using local assessment (Investigator assessment) 
based on RECIST 1.1.  In addition, images (including via other modalities) that are obtained at an unscheduled time point to determine disease progression, as well as imaging obtained for other reasons, but which demonstrate radiologic progression, should also be used to determine progression. 
When the Investigator identifies radiographic progression per RECIST 1.1, efforts should be 
made to verify radiologic  PD. Treatment should continue until PD has been verified.  
Regardless of whether PD is verified, if the Investigator considers the participant has 
progressed, but elects to implement i rRC, the Investigator will assess for confirmation of 
progression by i rRC at subsequent time points.   
7.1.2.6 Tumor Tissue Collection and Correlative Studies Blood Sampling  
7.1.2.6.1 Pharmacodynamic Analysis  
All biopsies on this trial are optional for patients. Whenever possible, archival tissue from a 
tumor lesion  will be obtained at screening. If archived tissue is not available, patients will be 
given the option to consent to a biopsy during the screening phase. Patients will also be given 
the option to consent to a biopsy on Day 14 of Cycle 1 (window -3 days). T he treatment 
biopsy should occur approximately 2 hours following the most recent dose of vorinostat on 
cycle 1 day 14. To ensure that these samples are obtained at the correct time, patients are 
urged to take their vorinostat dose in the clinic on the day of on- treatment sample collection.   
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 40 
 Biopsy for tumor tissue collection will only be done on patients who have accessible tumor 
per institutional guidelines. Missed tissue collection will not be considered a protocol deviation for the purposes of this study, as tissue collection is an exploratory objective for this study.  
Biomarker studies on tumor and blood biospecimens will be carried out to help understand the mechanism of action of the pembrolizumab  and vorinostat combination. The run- in phase 
will help  to assess the effect of single agents on the potential biomarkers. Results from these 
correlative studies will help in the identification of potential biomarkers of response to the pembrolizumab  plus vorinostat combination, ultimately leading to the devel opment of a 
patient selection strategy for further clinical investigation. As such, collection of tumor and blood biospecimens at baseline and on study will be of great importance.  
The p harmacodynamics of vorinostat and pembrolizumab  will be evaluated. Correlative 
studies will include assessment of immune effects Tregs, MDSCs and other immune cell s at 
defined time points per the study calendar (i.e., baseline, Run -in Phase Cycle - 2 Days 1 and 
14 [Dose Expansion Phase  only], Cycle 1  Day 1 before dosing, Cyc le 2 Day 1 before dosing, 
every other cycle day 1 before dosing thereafter , and at treatment discontinuation).  
Imaging studies (CT and bone scan) will be performed at baseline, before Cycle 3, every 3 
cycles thereafter and at treatment discontinuation.  
Relationships between vorinostat exposure an d pharmacodynamic effects (e.g.  histone 
acetylation in peripheral blood mononuclear c ells ( PBMNCs ) and changes in T  cell subset 
population) will be character ized. Samples will be processed, PBMNCs isolated and histone 
acetylation status determined. Blood samples will be analyzed for immune cell sub 
populations. CD4+, CD4+/Foxp3, CD8+ cells, NK cells will be quantitated by FACS 
analysis. Foxp3 gene expression w ill be evaluated by quantitative RTPCR   
 
Correlative studies on blood samples:  
o CD45 cells  
o Effector CD4 T cells  
o Effector CD8 T cells  
o FoxP3+ CD4+ Regulatory T cells (Tregs)  
o CD11b+ CD14+ HLA- DR low/neg MDSCs  
o Circulating microRNAs  
o Chemokines profile (i.e. IL -8, HFG, ostepontin, etc.)  
 
Correlative studies on tumor samples  
o T effector cells  
o Tregs  
o MDSCs  
o M1/M2 macrophages  
Please refer to the Study Procedures Manual for Sample Collection and Processing and shipping i nstructions.  

    
  IUSCC-0551  
Version 04/07/2021 NCT #02619253 41 
 7.1.2.6.2 Tumor Samples  
Formalin -Fixed Paraffin- Embedded Tissue : Archival tissue s amples may be obtained from 
any time prior to drug dosing from either the original diagnos is or from any subsequent biopsy 
done prior to start of first drug  treatment.  Paraffin blocks are preferred, but if unavailable, five 
(5) 4  micron sections and two  (2) to six (6) 10 micron sections from the same tumor block will 
be requeste d. 
Fresh tumor samples: P retreatment and On Treatment t umor biopsy samples will be collected 
from patients who consent and who have  accessible tumor per institutional procedure s. The 
biopsy sample will be split into two portions:  one (1) portion will be placed in RNAlaterTM  
and one (1) portion will be placed in 10% formalin solution.   
 
The On T reatment samples will be collected ~ 2 hours following the most recent dose of 
vorinostat on cycle 1 day 14 (- 3 days) .  To ensure that these samples are obtained at  the correct 
time, patients are urged to take their vorinostat dose in the clinic on the day of on -treatment 
sample collection. The time of the vorinostat dose and sample collection must be recorded. 
 
Please refer the Study Procedures Manual for additional  processing and shipping instructions. 
7.1.3 Laboratory Procedures/Assessments  
Details regarding specific laboratory procedures/assessments for hematology, chemistry, 
urinalysis, and others are specified in Table 5. The Schedule of Assessments - Section 6.0 summarizes the laboratory  procedures to be performed at each visit.  
Laboratory tests for screening or entry into the Retreatment  Phase should be performed 
within 10 days prior to the first dose of treatment.  After Cycle -2, pre-dose laboratory procedures can be conducted up to 72 hours prior to dosing.  Results must be reviewed by the investigator or qualified designee and found to be acceptable prior to each dose of trial 
treatment.  
      IUSCC- 0551  
Version 04/07/2021 NCT #02619253 42 
 Table 5:  Laboratory Tests  
Hematology  Chemistry  Urinalysis  Other  
Hematocrit  Albumin  Blood  Serum β -human chorionic gonadotropin † 
Hemoglobin  Alkaline phosphatase  Glucose    (β-hCG) † 
Platelet count  Alanine aminotransferase (ALT)  Protein  PT (INR)  
WBC (total and differential)  Aspartate aminotransferase (AST)  Specific gravity  aPTT  
Red Blood Cell Count  Lactate dehydrogenase (LDH)  Microscopic exam (If abnormal)   Total thriiodothyronine (T3)  
Absolute Neutrophil Count  Carbon Dioxide ‡ results are noted  Free tyroxine (T4)  
Absolute Lymphocyte Count    (CO 2 or biocarbonate)  Urine pregnancy test † Thyroid stimulating hormone (TSH)  
 Uric Acid   Blood for correlative studies   
 Calcium    
 Chloride    
 Glucose     
 Phosphorus     
 Potassium      
 Sodium     
 Magnesium     
 Total Bilirubin     
 Direct Bilirubin (If total bilirubin is 
elevated above the upper limit of 
normal)    
 Total protein    
 Blood Urea Nitrogen    
† Perform on women of childbearing potential only. If urine pregnancy results cannot be confirmed as negative, a serum pregnanc y test will be required.   
‡ If considered standard of care in your region.  
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 43 
 7.1.4 Other Procedures 
7.1.4.1 Withdrawal/Discontinuation  
When a subject discontinues/withdraws prior to trial completion, all applicable activities 
scheduled for the final trial visit should be performed at the time of discontinuation  whenever 
possible .  Any adverse events which are pr esent at the time of discontinuation/withdrawal 
should be followed in accordance with the safety require ments outlined in Section 7.2.  
Subjects who a) attain a CR or b) complete 24 months of treatment with pembrolizumab  may 
discontinue treatment with the option of restarting treatment if they meet the criteria specified in Section 7.1. 6.4.  After discontinuing treatment following assessment of CR, 
these subjects should return to the site for a Safety Follow -up Visit (described in Section 
7.1.6.1) and then proceed to the Follow -Up Period of the study (described in Section 7.1.6.2).  
7.1.4.2 Blinding/Unblinding  
This is an open -label trial.  
7.1.5 Visit Requirements  
Visit requirements are outlined in Section 6.0 -  Schedule of Assessments. Specific procedure -
related detai ls are provided above in Section 7.1 - Trial Procedures.  
7.1.6 Follow -up Requirements  
7.1.6.1 Safety Follow -up Visit 
The mandatory Safety Follow -up Visit should be conducted approximately 30 days after 
treatment discontinuation  or before the ini tiation of a new anti -cancer treatment, whichever 
comes first.  All AEs that occur prior to the Safety Follow -up Visit should be recorded.  
Subjects with an AE of Grade > 1 will be followed until the resolution of the AE to Grade 0-1 or until the beginning of a new anti -neoplastic therapy, whichever occurs first.  SAEs that 
occur within 90 days of the end of treatment or before initiation of a new anti- cancer  
treatment should also be followed and recorded.  Subjects who are eligible for retreatment 
with pembrolizumab (as described in Section 7.1. 6.4) may have up to two S afety F ollow -up 
Visits, one after the Treatment Period and one after the Retreatment  Phase.  
7.1.6.2 Follow -up Visits  
Subjects who discontinue trial treatment for a reason other than disease progression will move into the Fol low-up Phase and should be assessed per institutional guidelines by 
radiologic imaging to monitor disease status . Every effort should be made to collect 
information regarding disease status until the start of new anti -neoplastic therapy, disease 
progression, death, end of the study or if the subject begins retreatment with pembrolizumab  
as detailed in Section 7.1.6.4.  Information regarding post -study anti -neoplastic treatment 
will be collected if new treatment is initiated.  
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 44 
 Subjects who are eligible to receive retreatment with pembrolizumab  according to the criteria 
in Section 7.1.6.4 will move from the F ollow -Up Phase to the Retreatment Period  when they 
experience disease progression.  
7.1.6.3 Survival Follow -up 
Once a subject experiences confirmed disease progression or starts a new anti -cancer  
therapy, the subject moves into the survival follow -up phase and will be monitore d every 6 
months  (± 30  days ) to assess for survival status until death, withdrawal of consent, or the end 
of the study, whichever occurs first.  
7.1.6.4 Retreatment P hase  
Subjects who stop pembrolizumab with SD or better may be eligible for up to one year of 
additional pembrolizumab therapy if they progress after stopping study treatment.  This retreatment phase  is only available if the study remains open and the subject meets the 
following conditions:  
Either  
o Stopped initial treatment with pembrolizumab after attaining an investigator-determ ined confirmed CR according to RECIST 1.1 (Section 14.3) , and  
 Was treated for at least 24 weeks with pembrolizumab before discontinuing therapy  
 Received at least two treatments with pembrolizumab beyond the date when the initial CR was declared  
OR 
o Had SD, PR or CR and stopped pembrolizumab treatment after 24 months of study therapy for reasons other than disease progression or intolerability  
AND  
• Experienced an investigator -determined confirmed radiographic disease progression 
after stopping their initia l treatment with pembrolizumab  
• Did not receive any anti -cancer treatment since the last dose of pembrolizumab  
• Has a performance status of 0 or 1 on the ECOG Performance Scale  
• Demonstrates adequate organ function as detailed in Section 5.1.2 
• Female subject of childbearing potential should have a negative serum or urine 
pregnancy test within 72 hours prior to receiving retreatment with study medication.   
• Female subject of childbearing potential should be willing to use 2 methods of birth control or be surgic ally sterile, or abstain from heterosexual activity for the course of 
the study through 120 days after the last dose of study medication (reference Section 5.5.2).  Subjects of child bearing potential are those who have not been surgically sterilized or have been free from menses for > 1 year.  
• Male subject should agree to use an adequate method of contraception starting with 
the first dose of study therapy through 120 days after the last dose of study therapy.   
• Does not have a history or current evidence of any condition, therapy, or laboratory 
abnormality that might interfere with the subject’s participation for the full duration of the trial or is not in the best interest of the subject to participate, in the opinion of the treating investigator.  
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 45 
  
Subjec ts who restart treatment will be retreated at the same dose and dose interval as when 
they last received pembrolizumab.  Treatment will be administered for up to one additional year.  Subjects should be re -consented prior to start of re -treatment.  
 Visit requirements are outlined in Section 6.0 – Schedule of Assessments.  
 7.2 Assessing and Recording of Adverse Events  
7.2.1 Definitions of Adverse Events 
7.2.1.1 Adverse Event (AE)  
An adverse event is defined as untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An adverse event can be ANY unfavorable and unintended sign (e.g. an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medicinal (investigational) product, whe ther or not 
considered related to the medicinal (investigational) product (attribution of ‘unrelated’, ‘unlikely’, ‘possible’, ‘probable’, or ‘definite’).  Adverse events will be graded according to the NCI Common Toxicity Criteria, Version 4.0.  
7.2.1.2 Serious Ad verse Event (SAE)  
A serious adverse event is any untoward medical occurrence resulting in one or more of the following:  
• Results in death or ANY death occurring within 90 days of last dose of study drug 
(even if it is not felt to be drug related)  
• Is life -threatening (defined as an event in which the patient was at risk of death at the 
time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe)  
• Requires inpatient hospitalization or prolongation of exi sting hospitalization  
NOTE: Hospitalizations that are not considered SAEs are:  
o Hospitalization planned prior to first administration of study drug 
o Hospitalization for elective treatment of a pre -existing condition unrelated to the 
study medication  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly or birth defect  
• Is an important medical event (defined as a medical event(s) that may not be immediately life -threatening or result in death or hospitalization but,  based upon 
appropriate medical and scientific judgment, may jeopardize the patient or may require intervention (e.g., medical, surgical) to prevent one of the other serious outcomes listed in the definition above).  Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions not resulting in hospitalization; or the development of drug dependency or drug abuse.  
• Pregnancy  
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 46 
 o Pregnancy of a patient or of the female partn er of a male patient during the 
study or within 120 days after the last dose of study drug should be reported 
via an SAE report.  Should pregnancy occur in a female participant during the treatment period, study drug should be discontinued and Merck  notifi ed 
immediately.  Should a pregnancy occur in a female companion of a male participant during the treatment period, the male participant can continue treatment and Merck  notified immediately.  Any such pregnancy is to be 
followed until final outcome. Evalua ting Adverse Events  
• In addition to the above criteria, AEs meeting either of the below criteria, although not serious per ICH definition, are reportable to Merck in the same time frame as SAEs to meet certain local requirements. Therefore, these events are considered serious by Merck for collection purposes.  
o Is a new cancer (that is not a condition of the study)  
o Is associated with an overdose of pembrolizumab 
 An investigator who is a qualified physician will evaluate all adverse events according to the NCI Common Terminology for Adverse Events (CTCAE), version 4.0. Any adverse event which changes CTCAE grade over the course of a given episode will have each change of grade recorded on the adverse event case report forms/worksheets.  
All adverse events reg ardless of CTCAE grade must also be evaluated for seriousness.  
7.2.1.3 Unanticipated Problem  
Unanticipated Problem (UP):  any incident, experience, or outcome that meets all of the 
following criteria:  
1) unexpected (in terms of nature, severity, or frequency) given (a) the research procedures are described in the protocol -related documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the subject population being study;  
2) related or possibly related to participation in the research; and  
3) suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) related to the research than was previously known or recognized.  
Only  a small subset of adverse events occurring in human subjects participating in research 
will meet these three criteria for an unanticipated problem. Furthermore, there are other types of incidents, experiences, and outcomes that occur during the conduct of  human subjects 
research that represent unanticipated problems but are not considered adverse events. For 
example, some unanticipated problems involve social or economic harm instead of the physical 
or psychological harm associated with adverse events. In other cases, unanticipated problems place subjects or others at increased risk of harm, but no harm occurs.  
    
  IUSCC- 0551  
Version 04/07/2021 NCT #02619253 47 
 7.2.1.4 Unexpected Adverse Event  
An adverse event not mentioned in the Investigator's Brochure or package insert or the 
specificity or severity of which is not consistent with the Investigator's brochure or package insert.  
Refer to Table 6  for additional details regarding each of the above criteria. 
      IUSCC- 0551  
Version 04/07/2021 NCT #02619253 48 
 Table 6:  Evaluating Adverse Events  
An investigator who is a qualified physician, will evaluate all adverse events as to:  
V4.0 CTCAE 
Grading  Grade 1  Mild; asymptomatic or mid symptoms; clinical or diagnostic observations only; intervention not indicated.  
 Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.  
 Grade 3  Severe or medically significant but not immediately life -threatening; hospitalization or prolongation or hospitalization indicated; 
disabling; limiting self -care ADL.  
 Grade 4  Life threatening consequences; urgent intervention indicated.  
 Grade 5  Death related to AE  
Seriousness  A serious adverse event is any adverse event occurring at any dose or during any use of pembrolizumab or vorinostat  that: 
 †Results in death ; or 
 †Is life threatening; or  places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred (Note: This doe s not include an 
adverse event that, had it occurred in a more severe form, might have caused death.); or  
 †Results in a persiste nt or significant disability/incapacity  (substantial disruption of one’s ability to conduct normal life functions); or  
 †Results in or prolongs an existing inpatient hospitalization  (hospitalization is defined as an inpatient admission, regardless of leng th of stay, even if the 
hospitalization is a precautionary measure for continued observation. (Note: Hospitalization [including hospitalization for a n elective procedure] for a preexisting 
condition which has not worsened does not constitute a serious adve rse event.); or  
 †Is a congenital anomaly/birth defect  (in offspring of subject taking the product regardless of time to diagnosis);or  
 Is a new cancer;  (that is not a condition of the study)  or 
 Is an overdose  (whether accidental or intentional).  Any adverse event associated with an overdose is considered a serious adverse event. An  overdose that is not 
associated with an adverse event is considered a non -serious event of clinical interest and must be reported  within 24 hours.  
 Other important medical events  that may not result in death, not be life threatening, or not require hospitalization may be considered a serious adverse eve nt when, 
based upon appropriate medical judgment, the event may jeopardize the s ubject and may require medical or surgical intervention to prevent one of the outcomes 
listed previously (designated above by a †).  
Duration  Record the start and stop dates of the adverse event. If less than 1 day, indicate the appropriate length of time and units  
Action taken  Did the adverse event cause pembrolizumab or vorinostat  to be discontinued?  
Relationship to 
Pembrolizumab 
or Vorinostat  Did pembrolizumab or vorinostat  cause the adverse event? The determination of the likelihood that pembrolizumab or vorinostat  caused the adverse event will be 
provided by an investigator who is a qualified physician. The investigator’s signed/dated initials on the source document or worksheet that supports the causality 
noted on the AE form, ensures that a medically qualified ass essment of causality was done. This initialed document must be retained for the required regulatory time 
frame. The criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the tes t drug and the 
adverse event based upon the available information.  
The following components are to be used to assess the relationship between pembrolizumab or vorinostat  and the AE ; the greater the correlation with the 
components and their respective elem ents (in number and/or intensity), the more likely pembrolizumab or vorinostat  caused the adverse event (AE):  
 Exposure  Is there evidence that the subject was actually exposed to pembrolizumab or vorinostat  such as: reliable history, acceptable compliance 
assessment (pill count, diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?  
 Time Course  Did the AE follow in a reasonable temporal sequence from administration of pembrolizumab or vorinostat ?  
Is the time of onset of the AE compatible with a drug -induced effect?  
 Likely Cause  Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or  environmental 
factors  
 
      IUSCC- 0551  
Version 04/07/2021 NCT #02619253 49 
  
  
Relationship  The following components are to be used to assess the relationship between the test drug and the AE: (continued)  
to 
Pembrolizumab 
or Vorinostat  
(continued)  Dechallenge  Was pembrolizumab or vorinostat  discontinued or dose/exposure/frequency reduced?  
If yes, did the AE resolve or improve? 
If yes, this is a positive dechallenge. If no, this is a negative dechallenge.  
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the AE resolved/improved despite continuation 
of pembrolizumab or vorinostat ; or (3) the trial is a single -dose drug trial); or (4) pembrolizumab or vorin ostat  are only used one time.)  
 Rechallenge  Was the subject re -exposed to pembrolizumab or vorinostat  in this study?  
If yes, did the AE recur or worsen?  
If yes, this is a positive rechallenge. If no, this is a negative rechallenge.  
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the trial is  a single- dose drug trial); or 
(3) pembrolizumab or vorinostat  are used only one time).  
NOTE: IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN 
CAUSED BY PEMBROLIZUMAB OR VORINOSTAT, OR IF REEXPOSURE TO PEMBROLIZUMAB OR VORINOSTAT POSES 
ADDITIONAL POTENTIAL SIGNIFICANT RISK TO THE SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY THE  SPONSOR  AS PER DOSE MODIFICATION GUIDELINES IN THE PROTOCOL.  
 Consistency 
with Trial Treatment 
Profile  Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding the pembrolizumab or vorinostat  or drug class 
pharmacology or toxicology? 
The assessment of relationship will be reported on the case report forms /worksheets by an investigator who is a qualified ph ysician according to his/her best clinical judgment, including 
consideration of the above elements.  
Record one of the following  Use the following scale of criteria as guidance (not all criteria must be present to be indicative of  pembroli zumab or vorinostat  
relationship).  
Yes, there is a reasonable 
possibility of pembrolizumab or 
vorinostat  relationship.  There is evidence of exposure to pembrolizumab or vorinostat .  The temporal sequence of the AE onset relative to the administration of 
pembrolizumab or vorinostat  is reasonable.  The AE is more likely explained by pembrolizumab or vorinostat  than by another cause.  
No, there is not a reasonable 
possibility pembroli zumab or 
vorinostat  relationship Subject did not receive pembrolizumab or vorinostat  OR temporal sequence of the AE onset relative to administration of the pembrolizumab or 
vorinostat  is not reasonable OR there is another obvious cause of the AE.  (Also entered for a subject with overdose without an associated AE.)  
 
Version 04/07/2021 NCT #02619253 50 
 7.2.2 Definition of an Overdose  
For purposes of this trial, an overdose of pembrolizumab will be defined as any dose of 1,000 
mg or greater (≥5 times the indicated dose).  No specific i nformation is available on the 
treatment of overdose of pembrolizumab . Appropriate supportive treatment should be 
provided if clinically indicated. An overdose of vorinostat will be defined as any dose of ≥5 times the current dose being given (i.e. if 100 mg is indicated, 500 mg would be considered 
treatment overdose, and if 200 mg is indicated, 1000 mg would be considered treatment overdose). In the event of overdose, the subject should be observed closely for signs of 
toxicity.  Appropriate supportive tre atment should be provided if clinically indicated.  
If an adverse event(s)  is associated with (“results from”) the overdose of investigational  
product , the adverse event(s) is reported as a serious adverse event, even if no other 
seriousness criteria are met.  
If a dose of investigational product  meeting the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory results, the overdose is reported as a non- serious Event of Clinical Interest (ECI),  using the terminology “accidental 
or intentional overdose without adverse effect.”  
All reports of overdose with and without an adverse event must be reported  as described in 
sections 7. 2.5 and 10.5.  
7.2.3 Pregnancy and Lactation  
Although pregnancy and lactati on are not considered adverse events, it is the responsibility of 
investigators or their designees to report any pregnancy or lactation in a subject (spontaneously reported to them), including the pregnancy of a male subject's female partner that occurs during the trial or within 120 days of completing the trial , or 30 days following 
cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier .  
All subjects and female partners of male subjects who become pregnant must be fol lowed to 
the completion/termination of the pregnancy.  Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth must be reported as serious events (Imp ortant Medical Events).  If 
the pregnancy continues to term, the outcome (health of infant) must also be reported.  
Such events must be reported as within 24 hours to the Sponsor and within 2 working days to 
Merck Global Safety.  (Attn: Worldwide Product Safety; FAX 215 993- 1220)   
7.2.4 Events of Clinical Interest  
Selected non -serious and serious adverse events are also known as Events of Clinical Interest 
(ECI) and must be recorded as such on the Adverse Event case report forms and reported as described in sections 5.2.1.6 and 10.5. Events of Clinical I nterest for this trial include:  
1.  A n overdose of pembrolizumab , as defined in Section 7.2.2  - Definition of an Overdose, 
that is not associated with clinical symptoms or abnormal laboratory results.  
 
Version 04/07/2021 NCT #02619253 51 
 2.  A n elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that i s greater than or equal to 2X the upper 
limit of normal and, at the same time, an alkaline phosphatase lab value that is less than 2X 
the upper limit of normal, as determined by way of protocol- specified laboratory testing or 
unscheduled laboratory testing.* 
*Note:  These criteria are based upon available regulatory guidance documents. The purpose 
of the criteria is to specify a threshold of abnormal hepatic tests that may require an additional evaluation for an underlying etiology.  The trial site guidance for assessment and 
follow up of these criteria can be found in the Investigator Trial File Binder (or equivalent).  
3. Additional adverse events: 
A separate guidance document has been provided entitled “Event of Clinical Interest Guidance Document” (previousl y entitled, “Event of Clinical Interest and Immune -Related 
Adverse Event Guidance Document”). This document can be found in Appendix 14.5 and provides guidance regarding identification, evaluation and management of ECIs and irAEs.   
 ECIs (both non-serious and serious adverse events) identified in this guidance document 
from the date of first dose through 90 days following cessation of treatment, or 30 days after the initiation of a new anticancer therapy, whichever is earlier, need to be reported as descri bed in sections 5.2.1.6 and 10.5 regardless of attribution to study treatment, consistent 
with standard SAE reporting guidelines. 
 Subjects should be assessed for possible ECIs prior to each dose.  Lab results should be 
evaluated and subjects should be ask ed for signs and symptoms suggestive of an immune-
related event.  Subjects who develop an ECI thought to be immune-related should have additional testing to rule out other etiologic causes.  If lab results or symptoms indicate a possible immune -related ECI , then additional testing should be performed to rule out other 
etiologic causes.  If no other cause is found, then it is assumed to be immune- related.  
7.3 Participating Site Reporting Responsibilities  
7.3.1 Reporting SAEs, ECIs and Pregnancy to the Coordinating Cen ter (IU Simon  
Comprehensive Cancer Center)  
Any serious adverse event , unanticipated problem , event of clinical interest or pregnancy 
occurring from the first dose of vorinostat to within 90 days from the last dose of study drug 
must be reported to the IU S imon  Comprehensive Cancer Center within 24 hours  of 
notification or discovery of the incident, using the MedWatch Form 3500A (Mandatory Reporting). This form must be accompanied by a cover letter which:  identifies the event, is signed by the local principal investigator or treating physician, includes the applicable study number and title, and contains the following: 
• Site assessment of the event attribution to investigational treatment or study 
procedure 
• Site assessment of event expectedness (expected vs. unexpected)  
 
Version 04/07/2021 NCT #02619253 52 
 • Assessment of whether or not the research places subjects at a greater risk of harm 
than was previously known or recognized 
• Assessment of the event’s affect on the risk to benefit ratio  
• Statement as to whether the informed consent statement should reflect changes in the potential risks invo lved 
• Statement as to whether the event has been reported previously, and if so, whether the frequency is considered unusually high 
 
Send to:  IUSCC Clinical Trials Office  
ATTN: Multicenter coordinator/ IUSCC-0551 
   Preferred E- mail: IUSCCSAE@iu.edu
 
   Backup Fax: 317-944-3601 
 
All SAEs must also be entered into OnCore for monthly review  by the DSMC Coordinator. 
The Multicenter Network Administrator, or designee, wil l distribute  all reports meeting 
expedited reporting criteria to all participating sites, the FDA and to Merck . Copies of all 
serious adverse event reports will be kept on file in the IU Simon  Comprehensive Cancer 
Center Clinical Trials  Office . 
7.3.2 Follow- up of AE, SAE, and Other Reportable Safety Event Information 
7.3.3 After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. All AEs, SAEs, and other reportable safety events including pregna ncy and exposure during 
breastfeeding, events of clinical interest (ECIs), cancer, and overdose will be followed until resolution, stabilization, until the event is otherwise explained, or the participant is lost to follow -up.. In addition, the investigato r will make every 
attempt to follow all nonserious AEs that occur in allocated or randomized participants for outcome.  Reporting to the IRB  
Each participating site will report SAEs, ECIs, pregnancies, and unanticipated problems to their IRB per local and institutional guidelines. 
 
7.4 Coordinating Center Reporting Responsibilities  
7.4.1 Reporting to the IRB  
Unanticipated problems involving risks to subjects or others will be reported promptly to the 
IRB if they  are:  
• unexpected; 
• related or possibly related to participation in the research; and 
• suggests that the research places subjects or others at a greater risk of harm than 
was previously known or recognized.   
 
Version 04/07/2021 NCT #02619253 53 
  
If the unanticipated problem does not meet all three (3) criteria listed above, the event does not have to be promptly reported to the Indiana University IRB.  However, it should be reported at the time of continuing review.  Prompt reporting of unanticipated problems to the IRB is d efined as within 5 business days 
from becoming aware of the event.  7.4.2 Reporting to the FDA  
Per CFR 312.32 (c), the investigator-sponsor of the IND must notify the Food and Drug Administration (FDA) and all participating investigators in a written IND safety report of any 
adverse experience.  There are two types of reports to the FDA: 7 -day and 15-day reports. 
7-Day Reports: The investigator-sponsor must notify the FDA and all participating investigators in a written IND safety report of any adverse experience: 
• fatal or life -threatening experience that is both  
• suspected to be associated with use of the drug and  
• unexpected  (not in the investigator’s brochure)  
 
The FDA will be notified as soon as possible but no later than 7 calendar days  after initial 
receipt of the information.  
 15-Day IND Reports:  
Per CFR 312.32 (c), the investigator-sponsor of the IND must notify the Food and Drug Administration (FDA) and all participating investigators in a written IND safety report of any adverse experience:  
• suspected to be associated with use of the drug that is both   
• serious and  
• unexpected  (not in the investigator’s brochure) 
 
Each written notification shall be made as soon as possible, and no later than 15 calendar 
days  after the investigator- sponsor’s initi al receipt of the information.  
 
Report Content 
Each written notification may be submitted on FDA Form 3500A or in a narrative format and must bear prominent identification of its contents ( i.e., “IND Safety Report” ).  For purposes 
of this protocol, the MedWatch Report Form (FDA 3500A mandatory reporting), along 
with FDA Form 1571, and a cover letter  submitted to the appropriate FDA division, will 
serve as the written IND safety report.  Follow -up information to a safety report should be 
submitted as soon as the relevant information is available.  
Submit: 
• MedWatch Report Form (FDA 3500A) 
• FDA Form 1571 
• Cover Letter  
 
Version 04/07/2021 NCT #02619253 54 
  
Notify the FDA via phone or fax using MedWatch 3500A (mandatory reporting form)  
• Phone: 1- 888-463-6332, option #1  
• Fax: 1 -800-FDA- 0178  
 The IUSCC Protocol Development Coordinator should be co ntacted to assist with all FDA 
submissions and will be provided with a copy of all events that are reported to the FDA.    All IND submissions will be maintained in a master file in the IUSCC Clinical Trials Office.  
 7.4.3 Reporting to Merck  
SAEs, ECIs and pregnancy  reports and any other relevant safety information are to be 
forwarded to the Merck Global Safety facsimile number:  +1 -215-993-1220 within 2 working 
days  to Merck Global safety (Attn: Worldwide Product Safety; FAX 215 993- 1220) . 
A copy of all 15 Day Reports and FDA Annual Progress Reports as required by the FDA  will 
be submit ted to Merck & Co., Inc. (Attn: Worldwide Product Safety; FAX 215 993- 1220) at 
the time of submission to FDA.  Investigators will cross reference this submissi on, according 
to local regulations , to the Merck Investigational Compound Number (IND ) at the time of 
submission.   
All subjects with serious adverse ev ents must be followed up for outcome.  
 7.4.4 Reporting to Participating Sites  
For IND safety reports originating from this study, IUSCC  will distribute reports which are 
serious, unexpected and suspected to be associated with the study intervention (possibly, probably or definitely related) to all participating sites in the form of an Expedited Safety 
Report (exte rnal safety/IND report) within 15 calendar days from determination that the 
suspected adverse reaction qualifies for reporting. Copies of these Expedited Safety Reports 
will be kept on file in the IU Simon Comprehensive  Cancer Center Clinical Trials Office.  
When the sponsor(s) sends I ND safety reports from external studies that involve the study 
drug(s), Multicenter Network Associate Administrator, or designee, will forward  the reports 
to the sponsor -investigator .  The sponsor -investigator , or designee, w ill review these reports 
and determine if revisions are needed to the protocol or consent. IUSCC will forward these reports to participating sites every 2 weeks. 
If an adverse event or SAE requires modification of the in formed consent , protocol or other 
study documents , participating sites will be informed by way of an amendment and during 
weekly teleconferences, or sooner, as deemed necessary by the Principal Investigator.   
 
7.4.5 Reporting to the IUSCC Data Safety Monitoring Committee  (DSMC)   
Regardless of study sponsorship, the study team must enter all initial and follow -up SAE s, 
expedited, and noncompliance reports into OnCore
® for review by the DSMC chair and/or 
 
Version 04/07/2021 NCT #02619253 55 
 coordinator. Expedited reports may include IRB Prompt Report  Forms, MedWatch, and 
additional SAE forms as required by the sponsor. When follow -up information is received, a 
follow -up report should also be created in OnCore®. This DSMC reporting requirement is in 
addition to any other  regulatory bodies to be notifie d (i.e.  IRB, FDA, pharmaceutical 
company, etc.). The DSMC chair and/or coordinator will review all SAE, expedited, and 
noncompliance reports monthly.  
 8.0 STATISTICAL METHODS  
8.1 General Considerations 
Statistical analysis of this study will be the responsibility of the Department of Biostatistics at Indiana University School of Medicine. Parameter estimates and relevant summary statistics will be reported for both efficacy and safety outcomes. Continuous variables will be summarized by means, medians, minima, maxi ma and standard deviations. Categorical 
variables will be summarized by frequencies and percentages. Missing data will not be imputed. Additional exploratory analysis will be conducted when appropriate. Changes from the analysis plan will not require an am endment to the protocol unless it changes a significant 
feature in the protocol. The statistical analysis methods are outline below.  
8.2 Study Design 
This is an open -label phase I/Ib clinical trial. No randomization or blinding is involved. 
8.3 Analysis Population s 
8.3.1 Efficacy Population  
The efficacy population comprises all patients who meet the eligibility criteria, are registered onto the study, get at least one dose of study drug, and have at least one follow -up evaluation. 
This set will be used for efficacy analysis.  
8.3.2 Safety Population  
The safety population comprises all patients who have received at least one dose of the study medication. This set will be used for safety analysis.  
8.4 Sample Size, Accrual and Study Duration  
A minimum of 51 and maximum of 57  subjects ( 3-6 per 2 dose levels  in the escalation phase 
+ 45 in three expansion cohorts ) will be enrolled in this study. The primary sample size is 
dictated by the 3+3 design described earlier. Subjects not DLT evaluable in the finding  phase 
will be replaced. Three  expansion cohorts of  up to n = 15 subjects each will be used to 
measure efficacy endpoints and  is critical for the planning of the next phase of investigation. 
Having at least 12 patie nts per expansion cohort is adequate for the purposes of estimating 
effect sizes for larger trials for outcomes that are normally distributed or can be transformed to normality.
10 Increasing to 15 per group will help account for the possibility that a few 
subjects may not be evaluable for efficacy.  Subjects not evaluable for efficacy in the expansion phase will be replaced.   A subject is not evaluable for efficacy if they do not have 
at least one follow -up assessment of disease status after completing 1 cy cle of combination 
 
Version 04/07/2021 NCT #02619253 56 
 therapy. This could be either a scan or an assessment of symptomatic deterioration.  Accrual 
is expected to take up to 12 months.  
 8.5 Patient Characteristics  
Baseline patient characteristics will be tabulated, such as demographics (age, race, gender), and disease characteristics.  
8.6 Significant Protocol Violations  
Significant protocol violations such as with respect to eligibility criteria and treatment plan will be tabulated.  
8.7 Concomitant Medications  
Drugs that might affect the study medicatio n will be tabulated. 
8.8 Exposure and Compliance  
Exposure to the study medication will be summarized by frequencies and rates of the doses given. Reasons of not completing all doses will be tabulated.  
8.9 Efficacy Analysis  
Responses will be tabulated and objective response (CR+PR) via RECIST 1.1 will be summarized with the point estimate and corresponding exact 95%  confidence interval. For 
patients with prostate cancer PSA response (≥ 50% decline from baseline) , PSA progression 
(≥50% increase from baseline/nadir) and bone lesions progression on 
68Ga-PSMA -11 PET or 
bone scans (≥2 lesions from baseline with confirmatory scans 6 weeks later showing ≥2 
additional lesions) will be reported. Progression free and overall survival will be estimated 
using standard Kaplan- Meier curves. The  median time -to-event for each endpoint will be 
estimated along with the corresponding 95% confidence interval. Similar descriptive 
analyses will be performed using irRC criteria. Endpoints such as quantitative characteristics 
of humoral immun e response will be characterized by their  mean and corresponding 95% 
confidence interval. No statistical comparisons are planned. Analyses will be done separately 
by each expansion cohort . Patients enrolled in the Dose Finding Phase will be excluded when 
estimating efficacy for the design of a future trial. 
 
8.10 Safety Analysis  
Toxicities according to CTCAE 4.0 (see Section 14.2) will be summarized by frequencies 
and rates calculated as the proportion of patients in the safety population experiencing SAEs, 
discontinuations due to AEs, and AEs.  Two sets of tables will be generated: one for the 
overall toxicities and one for toxicities related to the study medication (possibly related, 
probably related and definitely related). Toxicities will be grouped by system using MedRA 
preferred terminology. Grade 1 to 4 will be reported individually and also as grade 3/4.  Deaths will be repor ted individually. AEs will be reported by dose finding cohort.  In the 
Dose Finding Phase, DLT's will be  evaluated in the first 21 days of therapy (see Section 
 
Version 04/07/2021 NCT #02619253 57 
 5.2.1.3). The AEs during the expansion phase will also be reported separately by expansion 
cohor t. 
Toxicity monitoring in the expansion phase will be continuous  with each expansion arm 
monitored separately .  We will consider the treatment to be excessively toxic if the 
probability of dose limiting toxicities in the first 21 days of therapy is  33% or greater.  The 
following table is based on exact binomial probabilities dropping below 0.10, which we will define as an unlikely possibili ty: 
 
Stop if number of DLTs  is: 3 4 5 6 7 8 
in N patients  3 4-6 7-8 9-10 11-13 14-15 
 
8.11 Interim Analysis  
No interim efficacy analysis will be performed  
9.0 DATA AND SAFETY MONITORING  
This study will be conducted in accordance with the IU Simon Comprehensive  Cancer Center 
Institution al DSMP for High Risk Trials.   
Investigators will conduct continuous review of data and subject safety. Weekly review 
meetings for high risk trials are required and will include the principal investigator, clinical research specialist and/or research nurse (other members per principal investigator’s discretion). Weekly meeting summaries should include review of data and subject safety by including for each dose level: the number of subjects, significant toxicities as described in the protocol, dose adjustments and responses observed. Study teams should maintain meeting minutes and attendance for submission to the DSMC upon request.   
9.1 Data Safety Monitoring Committee  
The IUSCC Data and Safety Monitoring Committee (DSMC) is responsible for oversight of 
subject safety, regulatory compliance, and data integrity for this trial.  The DSMC will 
review this study semi -annually to review overall trial progress, toxicity, compl iance, data 
integrity, and accrual per the Institutional DSMP.    Furthermore, the DSMC conducts an administrative review of serious adverse events (SAEs), 
deviations, reportable events, and any other outstanding business.  Major issues may require further DSMC review or action.   
 For any increase in frequency of grade 3 or above adverse events (above the rate reported in the Investigator Brochure or package insert), the principal investigator will notify the DSMC Chair immediately.  The notification will include the incidence of study adverse events, grades, and attributions, as well as investigator statements regarding comparison with risks per the IB/ package insert.     At any time during the conduct of the trial, if it is the opinion of the investigato rs that the risks 
(or benefits) to the subject warrant early closure of the study, the DSMC Chair and Compliance 
 
Version 04/07/2021 NCT #02619253 58 
 Officer must be notified within 1 business day via email, and the IRB must be notified within 
5 business days. Alternatively, the DSMC may init iate suspension or early closure of the study 
based on its review.  
9.2 DSMC DLT Review 
The principal investigator and study statistician will officially review all toxicity for each cohort of subjects prior to making dose escalation/expansion/de- escalation decisions.  Once a 
decision has been reached by the investigator, the official decision and toxicity data will be submitted to the DSMC via email (IUSCC- DLT -Review -L@list.iupui.edu
).  Treating 
additional subjects may not proceed until official DSMC correspondence confirms approval of dosing decisions for the next stage.   
 9.3 IND Annual Reports  
For trials with an IND held locally by the IU principal investigator or university, the IND Annual Report will be prepared and submitted to the Compliance Team.  This report will be reviewed and approved by the DSMC prior to FDA submission. 
 
9.4 Study Auditing and Monitoring  
All trials conducted at the IUSCC are subject to auditing and/or monitoring per the Institutional DSMP. Reports will be reviewed by the full DSMC at the time of study review.   9.5 Data Management/ Oncore Reporting Requirements  
The DSMC reviews data and study progress directly from Oncore; therefore, timely data entry and status updates are vital.  Study data must be entered within Oncore promptly, no later than one week from study visit occurrence.  Subject status in Oncore will be updated in 
real time, as this may affect overall trial enrollment status.  Global S AEs and deviations will 
be reviewed on a monthly basis by the DSMC Chair directly from Oncore.   
 9.6 Study Accrual Oversight  
Accrual data will be entered into the IU Simon Comprehensive Cancer Center OnCore system. The Protocol Progress Committee (PPC) revie ws study accrual twice per year, while 
the PPC coordinator reviews accrual quarterly.   9.7 Oncore Safety Reporting  
In addition to protocol- and regulatory-required safety reporting, all serious adverse events (SAEs) will be captured in the Oncore system within 1 business day of notification.  Initial SAE reporting will include as much detail as available, with follow -up to provide complete 
information.  Attributions will be assessed to study drugs, procedures, study disease, and other alternate etiology.      
 
Version 04/07/2021 NCT #02619253 59 
 9.8 Protocol Deviation Reporting  
Protocol deviations will be entered into OnCore within 5 days of discovery and reviewed by 
the DSMC Chair on a monthly basis. Findings will be reported to the full DSMC at the time of study review.  For serious or repetitive protocol deviations, additional action may be required by the DSMC.  
 
9.9 Data Acquisition  
Case Report Forms and Dat a Submission: This study will utilize electronic Case Report 
Form completion in the OnCore® database. A calendar of events and required forms are 
available in OnCore® at https://cancer.iu.edu/oncore.  The OnCore® database is a comprehensive database used b y the IUSCC CTO  and supported by the Indiana University 
Cancer Center.   
Access to data through OnCore® is restricted by user accounts and assigned roles.  Once logged into the OnCore® system with a user ID and password, OnCore® defines roles for each user which limits access to appropriate data.   
All source documents are to r emain in the patient’s clinic file.  All documents should be kept 
according to applicable federal guidelines.  Clinical trial data in OnCore® are periodically 
monitored by the IU Simon  Comprehensive  Cancer Center per the DSMC Charter.  
10.0  MULTICENTER G UIDELI NES  
10.1 Study Documents  
Each participating site must submit regulatory documents (informed consents, 1572s, Financial Disclosures, IRB approval documents, Continuing Reviews, Amendments, patient brochures or recruitment material etc.) to the Coordinating Cente r. The Coordinating Center 
will provide each site with a comprehensive list of the required documents prior to study start-up, throughout the duration of the study and upon study close -out. It is the responsibility 
of the participating site to maintain cop ies of all documentation sent to the Coordinating 
Center.  
10.2 Study Initiation  
Before activating the clinical trial at each participating site, the IUSCC CTO  Multicenter 
Network Administrator , or designee,  will ensure that:  
• Full Institutional Review Board (IRB) approval  has been obtained.  
• Research staff at the participating site has been trained in data entry into OnCore
®  
• A start -up meeting  with each institution has taken place via telephone 
conference. The start -up meeting will cover protocol detai ls (including eligibility 
 
Version 04/07/2021 NCT #02619253 60 
 criteria, treatment plan, etc.), responsibilities of the participating investigators, 
and reporting procedures.   
• A financial conflict of interest statement  from each investigator has been 
obtained. 
10.3 Patient Enrollment  
After eligibility is confirmed by the participating site staff, a completed eligibility checklist, supporting source documentation, and signed consent will be sent to IUSCC for verification.  The Multicenter Network Administrator, or designee, will confirm eligibility and return the 
enrollment information to the site.  The site staff will then register the patient in OnCore®. Additional details of this process can be found in the Study Procedure Manual. 
10.4 Data Monitoring 
All multicenter investigator initiated trials  conducted at the IUSCC are subject to data 
monitoring by the Multicenter Network Administrator, or designee. External sites will be 
notified of upcoming monitoring visits and will be expected to provide the Multicenter 
Network Administrator, or designee, with source documents for remote monitoring of 
patients.  Queries will be issued in OnCore ® and a detailed monitoring report will be 
provided to the participating site.  The IUSCC will also forward any monitoring and/or auditing reports to the DSMC .  
When a patient enrolled on this trial, or the trial itself, is selected for local monitoring or 
auditing, the participating site will forward the results to the Multicenter Network 
Administrator, or designee. In addition, if a participating site patient is selected for local auditing by the IUSCC DSMC, the site will be responsible for sending IUSCC de-identified source documents.  
10.5 Record Retention  
All documentation of adverse events, records of study drug receipt, dispensation, destruction, and all IRB correspondence will be stored in accordance with all applicable federal guidelines.  
Following closure of the study, each participating site will main tain a copy of all site study 
records in a safe and secure location. The Coordinating Center will inform the investigator at each site at such time that the records may be destroyed.  
11.0  LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL SUPPLIES  
11.1 Investigational Product  
The investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage, handling, distribution and usage of 
 
Version 04/07/2021 NCT #02619253 61 
 investigational product in accordance with the prot ocol and any applicable laws and 
regulations.  
Clinical Supplies will be provided by Merck as summarized in  Table 7 . 
  
 
Version 04/07/2021 NCT #02619253 62 
 Table 7:  Product Descriptions  
Product Name & Potency  Dosage Form  
Pembrolizumab  50 mg  Lyophilized Powder for Injection  
Pembrolizumab  100 mg/ 4mL  Solution for Injection  
Vorinostat 100 mg  Capsules  
 
11.2 Packaging and Labeling Information  
Clinical supplies will be affixed with a clinical label in accordance with regulatory 
requirements.  
11.3 Clinical Supplies Disclosure  
This trial is open -label; therefore, the subject, the trial site personnel, the Sponsor and/or 
designee are not blinded to treatment. Drug identity (name, strength) is included in the label text; random code/disclosure envelopes or lists are not provided. 
11.4 Stora ge and Handling Requirements  
Clinical supplies must be stored in a secure, limited -access location under the storage 
conditions specified on the label.   
Receipt and dispensing of trial medication must be recorded by an authorized person at the 
trial site.  
Clinical supplies may not be used for any purpose other than that stated in the protocol.  
11.5 Returns and Reconciliation  
The investigator is responsible for keeping accurate records of the clinical supplies received from Merck , or designee, the amount dispens ed to and returned by the subjects and the 
amount remaining at the conclusion of the trial.  
Upon completion  or termination of the study, all unused and/or  partially used 
investigational product will be destroyed at the site per institutional policy. It is the Investigat or’s respons ibility  to arrange for disposal of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local and institutional guidelines and procedures, a nd provided that appropriate records of 
disposal are kept.  
 
Version 04/07/2021 NCT #02619253 63 
 12.0 ADMINISTRATIVE AND REGULATORY DETAILS  
12.1 Compliance with Trial Registration and Results Posting Requirements  
Under the terms of the Food and Drug Administration Modernization Act (FDAMA) and the 
Food and Drug Administration Amendments Act (FDAAA), the Sponsor of the trial is solely responsible for determining whether the trial and its results are subject to the requirements for submission to the Clinical Trials Data Bank, http://www.clinicaltrials.gov.   Information 
posted will allow subjects to identify potentially appropriate trials for their disease conditions and pursue participation by calling a central contact number for further information on appropriate trial locations and trial site contact info rmation.     
  
 
Version 04/07/2021 NCT #02619253 64 
 13.0  REFERENCES  
1. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al . Safety and 
activity of anti- PD-L1 antibody in patients with advanced cancer. N Engl J Med. 
2012, 28;366(26):2455-65. 
2. Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, et al  Inhibition of 
PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder 
cancer (UBC). J Clin Oncol 32:5s, 2014 (suppl; abstr 5011).  
3. Kato Y, Yoshimura K, Shin T, Sanni T, Salumbides B, Schulick R, and Pili R. (2007) 
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS -275 in 
combination with interleukin 2 in a murine model of renal cell carcinoma . Clin 
Cancer Res. 13(15 Pt 1): 4538-46. 
4. Shen L, Ciesielski M, Ramakrishnan S, Miles K, Ellis L, Sotomayor Dr. Pili, Shrikant 
P, Fenstermaker R, Pili R. Class I histone deacetylase inhibitor entinostat suppresses 
regulatory T cells and enha nces immunotherapies in renal and prostate cancer models. 
PLoS ONE .2012;7(1):e30815. 
5. Pili R, Shen L, George S, Hammers HJ, Sandecki A, Collins C, Carducci MA. Phase I 
study of high-dose interleukin 2, aldesleukin, in combination with the histone 
deacetylase inhibitor, entinostat, in patients with metastatic renal cell carcinoma: 
Safety and tolerability results. J Clin Oncol 31, 2013 (suppl 6; abstr 369).  
6. Shen L, Pili R. Class I histone deacetylase inhibition is a novel mechanism to target 
regulatory T cells in immunotherapy.  Oncoimmunology. 2012 Sep 1;1(6):948-950. 
7. Atadja P  Development of the pan-DAC inhibitor panobinostat (LBH589): successes 
and challenges. Cancer Lett . 2009 Aug 8;280(2):233-41.  
8. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in 
patients with clear -cell renal cell carcinoma: a multicentre, single -arm phase I/II 
clinical trial. Pili R , Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge MA, 
Wahl R, Martin JI, Miles KM, Paesante S, Adelaiye R, Godoy A, King S, Zwiebel J, Carducci MA. Br J Cancer . 2017 Mar 28;116(7):874-883. 
9. Graff, J. N., Alumkal, J. J., Drake, C. G., Thomas, G. V., Redmond, W. L., Farhad, 
M., Cetnar, J. P., Ey, F. S., Bergan, R. C., Slottke, R., and Beer, T. M. (2016) Early 
evidence of anti -PD-1 activity in enzalutamide -resistant prostate cancer. Oncotarget.  
2016 Aug 16;7(33):52810-52817.  
10. Julious S. Sample size of 12 per group rule of thumb for a pilot study. 
Pharmaceut ical Statistics  2005, 4: 287-91. 
 
  
 
Version 04/07/2021 NCT #02619253 65 
 14.0  APPENDICES  
14.1 ECOG Performance Status 
Grade  Description  
0 Normal activity. Fully active, able to carry on all pre -disease 
performance without restriction.  
1 Symptoms, but ambulatory. Restricted in physically strenuous 
activity, but ambulatory and able to carry out work of a light or 
sedentary nature (e.g., light housework, office work).  
2 In bed <50% of the time. Ambulatory and capable of all self -care, 
but unable to carry out any work activities. Up and about more than 
50% of waking hours.  
3 In bed >50% of the time. Capable of only limited self -care, confined 
to bed or chair more than 50% of waking hours.  
4 100% bedridden. Completely disabled. Cannot carry on any self -
care. Totally confined to bed or chair.  
5 Dead.  
* As published in Am. J. Clin. Oncol.:  Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., 
McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative 
Oncology Group. Am J Clin Oncol 5:649 -655, 1982. The Eastern Cooperative Oncology Group, 
Robert Comis M.D., Group Chair.  
 
14.2 Common Terminology Criteria for Adverse Events V4.0 (CTCAE) 
Due to the size of the latest version of the Common Toxicity Criteria, copies of this appendix 
are not included with this protocol document. An electronic copy is available on the CTEP web site, http://ctep.cancer.gov/reporting/ctc.html
. 
 
14.3 Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria  for 
Evaluating Response in Solid Tumors  
RECIST version 1.1* will be used in this study for assessment of tumor response. While either CT or MRI may be utilized, as per RECIST 1.1, CT is the preferred imaging technique in this study.  The same imaging technique regarding modality, ideally the same scanner, and 
the use of contrast should be used in a participant throughout the study to optimize the reproducibility of the assessment of existing and new tumor burden and improve the accuracy of the assessment of response or progression based on imaging.  
* As published in the European Journal of Cancer: 
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar,  L. Dodd, R. Kaplan, D. Lacombe, J. Verweij. New response 
evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228 -
47. 
 
Version 04/07/2021 NCT #02619253 66 
 In addition, volumetric analysis will be explored by central review for response ass essment.  
14.3.1 Tumor Imaging and Assessment of Disease  
Tumor imaging is strongly preferred to be acquired by computed tomography (CT).  For the 
abdomen and pelvis, contrast -enhanced magnetic resonance imaging (MRI) may be used 
when CT with iodinated contrast is contraindicated, or when local practice mandates it.  MRI is the strongly preferred modality for imaging the brain.  The same imaging technique regarding modality, ideally the same scanner, and the use of contrast should be used in a participant throughout  the study to optimize the reproducibility of the assessment of existing 
and new tumor burden and improve the accuracy of the assessment of response or progression based on imaging.  
Expedited confirmation of measurable disease based on RECIST 1.1 at Screen ing should be 
used to determine participant eligibility.  Confirmation that the participant’s imaging shows at least 1 lesion that is appropriate for selection as a target lesion per RECIST 1.1 is highly recommended prior to participation starting  treatmen t.   
Participant eligibility will be determined using local assessment (Investigator assessment) based on RECIST 1.1.  In addition, images (including via other modalities) that are obtained at an unscheduled time point to determine disease progression, as well as imaging obtained for other reasons, but which demonstrate radiologic progression, should also be used to determine progression.  
When the Investigator identifies radiographic progression per RECIST 1.1, efforts should be made to verify radiologic PD . Treatment should continue until PD has been verified.     
14.3.2 Initial Tumor Imaging  
Initial tumor imaging at Screening must be performed within 28 days prior to the date of the 
first cycle .  The site study team must review screening images to confirm the participant has 
measurable disease per RECIST 1.1.  
The screening images must be submitted to the central imaging vendor for confirmation of measurable disease per RECIST 1.1 for eligibility prior to start of treatment.  
Tumor imaging performed as part of ro utine clinical management is acceptable for use as 
screening tumor imaging if they are of diagnostic quality and performed within 28 days prior to the date of cycle 1  and can be assessed by the central imaging vendor.  
14.3.3 Tumor Imaging During the Study  
The first on -study imaging assessment should be performed at 4 weeks ( 28 days - 7 days) 
from the date of screening .  Subsequent tumor imaging should be performed every 9  weeks 
(63 days ± 3 days) or more frequently if clinically indicated.  After 18 weeks ( 126 days ± 3 
days), participants who remain on treatment will have imaging performed every 9 weeks ( 63 
days ± 3 days).  Imaging timing should follow calendar days and should not be adjusted for 
 
Version 04/07/2021 NCT #02619253 67 
 delays in cycle starts.  Imaging should continue to be performed until disease progression is 
identified by the Investigator .  
Objective response should be confirmed by a repeat imaging assessment.  Tumor imaging to confirm PR or CR should be performed at least 4  weeks after the first indication of a 
response i s observed.  Participants will then return to regular scheduled imaging ever y 9 
weeks, starting with the next scheduled imaging time point.  Participants who receive additional imaging for confirmation do not need to undergo the next scheduled tumor imagin g if it is less than 4 weeks later; tumor imaging may resume at the subsequent 
scheduled imaging time point.   
14.3.4 End of Treatment and Follow -up Tumor Imaging  
In participants who discontinue study treatment, tumor imaging should be performed at the 
time of treatment discontinuation (±4 week window).  If previous imaging was obtained within 4 weeks prior to the date of discontinuation, then imaging at treatment discontinuation is not mandatory. In participants who discontinue study treatment due to documented disease 
progression and the investigator elects not to implement iRECIST, this is the final required tumor imaging.  
For participants who discontinue study treatment without documented disease progression, every effort should be made to continue monitoring their disease status by tumor imaging using 
the same imaging schedule used while on treatment (every 9 weeks in Year 1 or every 6 months  
after Year 1) to monitor disease status until the start of a new anticancer treatment, disease progression, pregnancy,  death, withdrawal of consent, or the end of the study, whichever 
occurs first.  
14.3.5 Second Course (Retreatment) Tumor Imaging  
Tumor imaging must be performed within 10 days prior to restarting treatment with 
pembrolizumab.  Local reading (Investigator assessment with site radiology reading) will be  
used to determine eligibility.  
The first on -study imaging assessment should be performed at 9 weeks ( 63 days ± 3 days) 
after the restart of treatment.  Subsequent tumor imaging should be performed every 9 weeks 
(63 days ± 3 days) or more frequently, if clinically indicated.  
Per RECIST 1.1, if tumor imaging shows initial PD, tumor assessment should be repeated 4 to 8 weeks later in order to confirm PD  with the option of continuing treatment while 
awaiting radiologic confirmation of progression  with the option of continuing treatment 
while awaiting radiological confirmation of progression in clinically stable patients .  
Participants who obtain confirmatory imaging do not need to undergo scheduled tumor 
imaging if it is less than 4  weeks later and may wait until the next scheduled imaging time 
point, if clinically stable . 
Imaging should continue to be performed until disease progression, the start of a new anticancer treatment, withdrawal of consent, death, or notification by the Sponsor, whichever 
 
Version 04/07/2021 NCT #02619253 68 
 occurs first.  Disease progression may be confirmed 4 to 8 weeks after the f irst tumor 
imaging indicating PD, in clinically stable participants.  
In participants who discontinue study treatment, tumor imaging should be performed at the 
time of treatment discontinuation (±4 week window).  If previous imaging was obtained within 4  weeks prior to the date of discontinuation, then imaging at treatment discontinuation 
is not mandatory.  For  participants who discontinue study treatment due to documented 
disease progression, this is the final required tumor imaging.  
For participants who di scontinue study treatment without documented disease progression, 
every effort should be made to continue monitoring their disease status by radiologic imaging every  6 months  (180 days ±14 days) until either the start of a new anticancer treatment, 
disease progression, pregnancy, death,  or the end of the study, whichever occurs first.  
  
 
Version 04/07/2021 NCT #02619253 69 
 14.4 Drug Diary  
 
 
      

 
Version 04/07/2021 NCT #02619253 70 
 14.5 Events of Clinical Interest Guidance Document  
Attached as PDF entitled, “ Pembrolizumab ECI_Guidance 
Document_Version 5_FINAL_18-Dec -2014 ” 
 
 
 
14.6  Woman of Childbearing Potential (WOCBP)  definition  
A woman is considered fertile following menarche and until becoming post-menopausal 
unless permanently sterile (see below)  
Women in the following categories are not considered WO CBP:  
● Premenarchal  
● Premenopausal female with 1 of the following:  
○ Documented hysterectomy  
○ Documented bilateral salpingectomy  
○ Documented bilateral oophorectomy  
Note:  Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
● Postmenopausal female  
○ A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  ▪ A high follicle stimulating hormone (FSH) level in the postmenopausal range may 
be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with two FSH measurements in the postmenopausal range is required.  
○ Females on HRT and whose menopausal status is in doubt will be required to use one 
of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
  
 
Version 04/07/2021 NCT #02619253 71 
 14.7 Immune -Related Response Criteria  
INTRODUCTION  
Increasing clinical experience indicates that traditional response criteria (e.g.,  Response Evaluation 
Criteria in Solid Tumors, Version 1.1 [RECIST v1.1] and World Health Organization [WHO]) may 
not be suffici ent to characterize fully activity in the new era of target therapies and/or biologics.  In 
studies with cytokines, cancer vaccines, and  monoclonal antibodies, complete response, partial 
response, or stable disease has been shown to occur after an increase in tumor burden as characterized 
by progressive disease by traditional response criteria.  Therefore, conventional response criteria may 
not adequately assess the activity of immunotherapeutic agents because progressive disease (by initial radiographic evaluation) does not necessarily reflect therapeutic failure.  Long -term effect on the 
target disease must also be captured.  The immune-related response criteria
1 (irRC) are criteria that 
attempt to do that by enhancing characterization of new response pat terns that have been observed 
with immunotherapeutic agents (i.e., ipilimumab).  (Note:  The irRC only index and measurable new 
lesions are taken into  account.)  
GLOSSARY  
Term  Definition  
SPD sum of the products of the two largest perpendicular diameters  
Tumor burden  SPD index lesions  + SPD new, measurable lesions  
Nadir  minimally recorded tumor burden  
irCR immune -related complete response  
irPD  immune -related progressive disease 
irPR immune -related partial response  
irSD  immune -related stable disease 
irBOR  immune -related best overall response  
 
BASELINE ASSESSMENT USING ir RC 
Step 1. Identify the index lesions (five lesions per organ, up to ten visceral lesions and five  cutaneous 
lesions).   
Step 2. Calculate the SPD of all of these index lesio ns: 
SPD  = (Largest diameter of lesion i)  × (Second largest diameter of lesion i).  
 
1  Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: 
immune -related response criteria. Clin Can Res 2009;15:7412 −20. ∑
i
 
Version 04/07/2021 NCT #02619253 72 
 POST -BASELINE ASSESSMENTS USING irRC 
Step 1. Calculate the SPD of the index lesions.   
Step 2. Identify new, measurable lesions ( ≥ 5 × 5 mm; up to five new lesions per organ:  five  new 
cutaneous lesions and ten visceral lesions).   
Step 3. Calculate the SPD of the new, measurable lesions.  
Step 4. Calculate the tumor burden:  
Tumor burden  =  SPD index lesions  + SPD new, measurable lesions  
Step 5. Calculate the change in tumor burden relative to baseline and the change in tumor burden 
relative to nadir.  
Step 6. Derive the overall response using the table below.  
Overall  Response  Criterion 
irCR  Complete disappearance of all lesions (whether meas urable or not, and no new 
lesions) confirmed by a repeat, consecutive assessment ≥  4 weeks from the date 
first documented  
irPR Decrease in tumor burden ≥ 50% relative to baseline confirmed by a 
consecutive assessment ≥  4 weeks from the date first documented  
irSD  Criteria for irCR, irPR, and irPD are not met; does not require confirmation  
irPD  Increase in tumor burden ≥ 25% relative to nadir confirmed by a  consecutive 
assessment ≥  4 weeks from the date first documented  
irCR = immune -related complete response; irPD  = immune -related progressive disease; 
irPR = immune -related partial response; irSD  = immune -related stable disease.  
 
DETERMINATION OF ir BOR 
Once a patient has completed all tumor assessments, his/her irBOR may be determined:  
Condition  irBOR 
At least one irCR  irCR  
At least one irPR and no irCR  irPR 
At least one irSD and no irCR and no irPR  irSD  
At least one irPD and no irCR, no irPR, and no irSD  irPD  
irBOR = immune -related best overall response; irCR = immune -related complete response; 
irPD  = immune -related progressive disease; irPR = immune -related partial response; 
irSD  = immune -related stable disease.  
 